BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 2005;40:225-235. [PMID: 15830281 DOI: 10.1007/s00535-005-1566-3] [Cited by in Crossref: 370] [Cited by in F6Publishing: 320] [Article Influence: 23.1] [Reference Citation Analysis]
Number Citing Articles
1 Kim JH, Yoon HK, Kim SY, Kim KM, Ko GY, Gwon DI, Sung KB. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther. 2009;29:1291-1298. [PMID: 19392861 DOI: 10.1111/j.1365-2036.2009.04016.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
2 Wang D, Gaba RC, Jin B, Riaz A, Lewandowski RJ, Ryu RK, Sato KT, Ragin AB, Kulik LM, Mulcahy MF, Salem R, Larson AC, Omary RA. Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinoma. Acad Radiol 2011;18:828-36. [PMID: 21669349 DOI: 10.1016/j.acra.2011.02.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
3 Komatsu S, Hori Y, Fukumoto T, Murakami M, Hishikawa Y, Ku Y. Surgical spacer placement and proton radiotherapy for unresectable hepatocellular carcinoma. World J Gastroenterol 2010;16:1800-3. [PMID: 20380016 DOI: 10.3748/wjg.v16.i14.1800] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
4 Zhao H, Meng Y, Zhai X, Cheng B, Yu S, Yao M, Yin H, Wan X, Yang Y, Liu H, Shen F, Ling C. Comparable effects of Jiedu Granule, a compound Chinese herbal medicine, and sorafenib for advanced hepatocellular carcinoma: A prospective multicenter cohort study. Journal of Integrative Medicine 2020;18:319-25. [DOI: 10.1016/j.joim.2020.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Richly H, Schultheis B, Adamietz IA, Kupsch P, Grubert M, Hilger RA, Ludwig M, Brendel E, Christensen O, Strumberg D. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur J Cancer. 2009;45:579-587. [PMID: 19101137 DOI: 10.1016/j.ejca.2008.10.039] [Cited by in Crossref: 49] [Cited by in F6Publishing: 55] [Article Influence: 3.8] [Reference Citation Analysis]
6 Khan T, Ali M, Khan A, Nisar P, Jan SA, Afridi S, Shinwari ZK. Anticancer Plants: A Review of the Active Phytochemicals, Applications in Animal Models, and Regulatory Aspects. Biomolecules 2019;10:E47. [PMID: 31892257 DOI: 10.3390/biom10010047] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 13.5] [Reference Citation Analysis]
7 Yeh YC, Liu CJ, Kuo RN, Lai CL, Shau WY, Chen PJ, Lai MS. Association of adjuvant antiviral therapy with risk of cancer progression and deaths in patients with hepatitis-B-virus-related hepatocellular carcinoma following curative treatment: a nationwide cohort study. PLoS One. 2014;9:e102051. [PMID: 25025231 DOI: 10.1371/journal.pone.0102051] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
8 Wang W, Feng X, Zhang T, Jin J, Wang S, Liu Y, Song Y, Liu X, Yu Z, Li Y. Prospective evaluation of microscopic extension using whole-mount preparation in patients with hepatocellular carcinoma: Definition of clinical target volume for radiotherapy. Radiat Oncol 2010;5:73. [PMID: 20731853 DOI: 10.1186/1748-717X-5-73] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
9 Chung Y, Han G, Yoon J, Yang J, Wang J, Shao G, Kim BI, Lee T, Chao Y. Interim analysis of START: Study in asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. Int J Cancer 2013;132:2448-58. [DOI: 10.1002/ijc.27925] [Cited by in Crossref: 53] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
10 Zhu ZX, Liao MH, Wang XX, Huang JW. Transcatheter Arterial Chemoembolization Plus 131I-Labelled Metuximab versus Transcatheter Arterial Chemoembolization Alone in Intermediate/Advanced Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Korean J Radiol 2016;17:882-92. [PMID: 27833404 DOI: 10.3348/kjr.2016.17.6.882] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
11 Zheng R, You Z, Jia J, Lin S, Han S, Liu A, Long H, Wang S. Curcumin enhances the antitumor effect of ABT-737 via activation of the ROS-ASK1-JNK pathway in hepatocellular carcinoma cells. Mol Med Rep 2016;13:1570-6. [PMID: 26707143 DOI: 10.3892/mmr.2015.4715] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
12 Dos Santos DC, Rafique J, Saba S, Almeida GM, Siminski T, Pádua C, Filho DW, Zamoner A, Braga AL, Pedrosa RC, Ourique F. Apoptosis oxidative damage-mediated and antiproliferative effect of selenylated imidazo[1,2-a]pyridines on hepatocellular carcinoma HepG2 cells and in vivo. J Biochem Mol Toxicol 2021;35:e22663. [PMID: 33125183 DOI: 10.1002/jbt.22663] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
13 Yoo D, Kim KM, Jin Y, Shim JH, Ko G, Yoon H, Sung K, Lee J, Kang Y, Lim Y, Lee HC, Chung Y, Lee YS, Suh DJ. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: Does transarterial chemoembolization improve survival in these patients?: Efficacy of TACE in HCC with metastasis. Journal of Gastroenterology and Hepatology 2011;26:145-54. [DOI: 10.1111/j.1440-1746.2010.06341.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 6.6] [Reference Citation Analysis]
14 Yang B, Qian F, Li W, Li Y, Han Y. Effects of general anesthesia with or without epidural block on tumor metastasis and mechanisms. Oncol Lett 2018;15:4662-8. [PMID: 29541238 DOI: 10.3892/ol.2018.7870] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Pan QZ, Wang QJ, Dan JQ, Pan K, Li YQ, Zhang YJ, Zhao JJ, Weng DS, Tang Y, Huang LX, He J, Chen SP, Ke ML, Chen MS, Wicha MS, Chang AE, Zeng YX, Li Q, Xia JC. A nomogram for predicting the benefit of adjuvant cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. Sci Rep. 2015;5:9202. [PMID: 25776856 DOI: 10.1038/srep09202] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
16 Evdokimova VN, Butterfield LH. Alpha-fetoprotein and other tumour-associated antigens for immunotherapy of hepatocellular cancer. Expert Opin Biol Ther 2008;8:325-36. [PMID: 18294103 DOI: 10.1517/14712598.8.3.325] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
17 Kobayashi S, Nouso K, Kinugasa H, Takeuchi Y, Tomoda T, Miyahara K, Hagihara H, Kuwaki K, Onishi H, Nakamura S, Ikeda F, Miyake Y, Shiraha H, Takaki A, Yamamoto K. Clinical utility of serum fucosylated hemopexin in Japanese patients with hepatocellular carcinoma: Fucosylated hemopexin and HCC. Hepatology Research 2012;42:1187-95. [DOI: 10.1111/j.1872-034x.2012.01044.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
18 Nii A, Shimada M, Ikegami T, Harino Y, Imura S, Morine Y, Kanemura H, Arakawa Y, Sugimoto K. Significance of dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expressions in hepatocellular carcinoma. Hepatol Res 2009;39:274-81. [PMID: 19054147 DOI: 10.1111/j.1872-034X.2008.00457.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
19 Moon H, Choi JE, Lee IJ, Kim TH, Kim SH, Ko YH, Kim HB, Nam BH, Park JW. All-treatment array of hepatocellular carcinoma from initial diagnosis to death: observation of cumulative treatments. J Cancer Res Clin Oncol 2017;143:2327-39. [PMID: 28744575 DOI: 10.1007/s00432-017-2480-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Kim HC, Suk KT, Kim DJ, Yoon JH, Kim YS, Baik GH, Kim JB, Kim CH, Sung H, Choi JY, Han KH, Park SH. Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. World J Gastroenterol 2014;20:745-54. [PMID: 24574748 DOI: 10.3748/wjg.v20.i3.745] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
21 Chen J, Shen BY, Deng XX, Zhan Q, Peng CH. SKP1-CULLIN1-F-box (SCF)-mediated DRG2 degradation facilitated chemotherapeutic drugs induced apoptosis in hepatocellular carcinoma cells. Biochem Biophys Res Commun 2012;420:651-5. [PMID: 22450327 DOI: 10.1016/j.bbrc.2012.03.058] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
22 Zeeneldin AA, Salem SE, Tabashy RH, Ibrahim AA, Alieldin NH. Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a single center experience including 221 patients. J Egypt Natl Canc Inst 2013;25:143-50. [PMID: 23932751 DOI: 10.1016/j.jnci.2013.05.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
23 Moustafa AS, Abdel Aal AK, Ertel N, Saad N, DuBay D, Saddekni S. Chemoembolization of Hepatocellular Carcinoma with Extrahepatic Collateral Blood Supply: Anatomic and Technical Considerations. Radiographics 2017;37:963-77. [PMID: 28362557 DOI: 10.1148/rg.2017160122] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
24 Santos NP, Colaço AA, Oliveira PA. Animal models as a tool in hepatocellular carcinoma research: A Review. Tumour Biol 2017;39:1010428317695923. [PMID: 28347231 DOI: 10.1177/1010428317695923] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 11.5] [Reference Citation Analysis]
25 Miyahara K, Nouso K, Morimoto Y, Takeuchi Y, Hagihara H, Kuwaki K, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Honda M, Kaneko S, Sato T, Sato S, Obi S, Iwadou S, Kobayashi Y, Takaguchi K, Kariyama K, Takuma Y, Takabatake H, Yamamoto K;  Okayama Liver Cancer Group. Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma. Br J Cancer. 2013;109:2072-2078. [PMID: 24045661 DOI: 10.1038/bjc.2013.554] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
26 Kondo K, Chijiiwa K, Kai M, Otani K, Nagaike K, Ohuchida J, Hiyoshi M, Nagano M. Surgical strategy for hepatocellular carcinoma patients with portal vein tumor thrombus based on prognostic factors. J Gastrointest Surg. 2009;13:1078-1083. [PMID: 19296182 DOI: 10.1007/s11605-009-0854-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
27 Zhang Z, Zhang H, Peng T, Li D, Xu J. Melittin suppresses cathepsin S-induced invasion and angiogenesis via blocking of the VEGF-A/VEGFR-2/MEK1/ERK1/2 pathway in human hepatocellular carcinoma. Oncol Lett 2016;11:610-8. [PMID: 26870255 DOI: 10.3892/ol.2015.3957] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
28 Chen W, Wu Y, Liu W, Wang G, Wang X, Yang Y, Chen W, Tai Y, Lu M, Qian Q, Zhang Q, Chen G. Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma. Cancer Lett 2011;307:93-103. [PMID: 21504839 DOI: 10.1016/j.canlet.2011.03.021] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
29 Park YK, Song SK, Kim BW, Park SK, Chung CW, Wang HJ. Prognostic significance of microvascular invasion in tumor stage for hepatocellular carcinoma. World J Surg Oncol 2017;15:225. [PMID: 29258507 DOI: 10.1186/s12957-017-1292-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
30 Kim RD, Reed AI, Fujita S, Foley DP, Mekeel KL, Hemming AW. Consensus and controversy in the management of hepatocellular carcinoma. J Am Coll Surg. 2007;205:108-123. [PMID: 17617340 DOI: 10.1016/j.jamcollsurg.2007.02.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
31 Tummala KS, Djouder N. Oncogene-induced NAD(+) depletion in tumorigenesis. Oncoscience 2015;2:318-9. [PMID: 26097866 DOI: 10.18632/oncoscience.154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Mazzocca A, Fransvea E, Lavezzari G, Antonaci S, Giannelli G. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology. 2009;50:1140-1151. [PMID: 19711426 DOI: 10.1002/hep.23118] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 6.7] [Reference Citation Analysis]
33 Sacco R, Bertini M, Petruzzi P, Bertoni M, Bargellini I, Bresci G, Federici G, Gambardella L, Metrangolo S, Parisi G, Romano A, Scaramuzzino A, Tumino E, Silvestri A, Altomare E, Vignali C, Capria A. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study. World J Gastroenterol 2009;15:1843-8. [PMID: 19370781 DOI: 10.3748/wjg.15.1843] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
34 Thoppil RJ, Bishayee A. Terpenoids as potential chemopreventive and therapeutic agents in liver cancer. World J Hepatol 2011;3:228-49. [PMID: 21969877 DOI: 10.4254/wjh.v3.i9.228] [Cited by in Crossref: 146] [Cited by in F6Publishing: 92] [Article Influence: 14.6] [Reference Citation Analysis]
35 Deng YR, Liu WB, Lian ZX, Li X, Hou X. Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma. Oncotarget 2016;7:38292-305. [PMID: 27203677 DOI: 10.18632/oncotarget.9438] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 12.3] [Reference Citation Analysis]
36 Martins A, Cortez-Pinto H, Marques-Vidal P, Mendes N, Silva S, Fatela N, Glória H, Marinho R, Távora I, Ramalho F. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int. 2006;26:680-687. [PMID: 16842324 DOI: 10.1111/j.1478-3231.2006.001285.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
37 Zhao L, Chen Z, Wang J, Yang L, Zhao Q, Wang J, Qi Q, Mu R, You Q, Guo Q. Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice. Cancer Chemother Pharmacol 2010;65:481-9. [DOI: 10.1007/s00280-009-1053-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
38 Sun GP, Wang H, Xu SP, Shen YX, Wu Q, Chen ZD, Wei W. Anti-tumor effects of paeonol in a HepA-hepatoma bearing mouse model via induction of tumor cell apoptosis and stimulation of IL-2 and TNF-alpha production. Eur J Pharmacol 2008;584:246-52. [PMID: 18329639 DOI: 10.1016/j.ejphar.2008.02.016] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
39 Sugimachi K, Ikeda Y, Tomikawa M, Taketomi A, Tsukamoto S, Kawasaki K, Yamamura S, Korenaga D, Maehara Y, Takenaka K. Appraisal of hepatic resection in the treatment of hepatocellular carcinoma with severe thrombocytopenia. World J Surg. 2008;32:1077-1081. [PMID: 18338210 DOI: 10.1007/s00268-007-9442-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
40 Zhang Y, Zhang JW, Lv GY, Xie SL, Wang GY. Effects of STAT3 gene silencing and rapamycin on apoptosis in hepatocarcinoma cells. Int J Med Sci. 2012;9:216-224. [PMID: 22408571 DOI: 10.7150/ijms.4004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
41 Cetin M, Odabas G, Douglas LR, Duriez PJ, Balcik-Ercin P, Yalim-Camci I, Sayan AE, Yagci T. ROR1 Expression and Its Functional Significance in Hepatocellular Carcinoma Cells. Cells 2019;8:E210. [PMID: 30832318 DOI: 10.3390/cells8030210] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
42 Tanaka S, Mogushi K, Yasen M, Ban D, Noguchi N, Irie T, Kudo A, Nakamura N, Tanaka H, Yamamoto M. Oxidative stress pathways in noncancerous human liver tissue to predict hepatocellular carcinoma recurrence: a prospective, multicenter study. Hepatology. 2011;54:1273-1281. [PMID: 22006857 DOI: 10.1002/hep.24536] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
43 Nagamatsu H, Hiraki M, Mizukami N, Yoshida H, Iwamoto H, Sumie S, Torimura T, Sata M. Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. Aliment Pharmacol Ther. 2010;32:543-550. [PMID: 20500734 DOI: 10.1111/j.1365-2036.2010.04379.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
44 Kondo K, Chijiiwa K, Funagayama M, Kai M, Otani K, Ohuchida J. Differences in long-term outcome and prognostic factors according to viral status in patients with hepatocellular carcinoma treated by surgery. J Gastrointest Surg. 2008;12:468-476. [PMID: 17999119 DOI: 10.1007/s11605-007-0402-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
45 Thelen A, Jonas S, Benckert C, Weichert W, Schott E, Bötcher C, Dietz E, Wiedenmann B, Neuhaus P, Scholz A. Tumor-associated lymphangiogenesis correlates with prognosis after resection of human hepatocellular carcinoma. Ann Surg Oncol 2009;16:1222-30. [PMID: 19224279 DOI: 10.1245/s10434-009-0380-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
46 Yokoyama K, Anan A, Iwata K, Nishizawa S, Morihara D, Ueda S, Sakurai K, Iwashita H, Hirano G, Sakamoto M. Limitation of repeated radiofrequency ablation in hepatocellular carcinoma: proposal of a three (times) × 3 (years) index. J Gastroenterol Hepatol. 2012;27:1044-1050. [PMID: 22433056 DOI: 10.1111/j.1440-1746.2012.07134.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
47 Matos JM, Witzmann FA, Cummings OW, Schmidt CM. A pilot study of proteomic profiles of human hepatocellular carcinoma in the United States. J Surg Res 2009;155:237-43. [PMID: 19535095 DOI: 10.1016/j.jss.2008.06.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
48 Schaudt A, Kriener S, Schwarz W, Wullstein C, Zangos S, Vogl T, Mehrabi A, Fonouni H, Bechstein WO, Golling M. Role of transarterial chemoembolization for hepatocellular carcinoma before liver transplantation with special consideration of tumor necrosis. Clin Transplant 2009;23 Suppl 21:61-7. [PMID: 19930318 DOI: 10.1111/j.1399-0012.2009.01111.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
49 Zeeneldin AA, Eid SM, Darweesh AD, Moneer MM, Saadeldin M. Tamoxifen compared to best supportive care in advanced hepatocelluar carcinoma: A retrospective matched-cohort study. J Egypt Natl Canc Inst 2014;26:1-7. [PMID: 24565676 DOI: 10.1016/j.jnci.2013.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
50 Padma S, Martinie JB, Iannitti DA. Liver tumor ablation: Percutaneous and open approaches. J Surg Oncol. 2009;100:619-634. [PMID: 20017157 DOI: 10.1002/jso.21364] [Cited by in Crossref: 68] [Cited by in F6Publishing: 51] [Article Influence: 6.2] [Reference Citation Analysis]
51 Sanuki N, Takeda A, Kunieda E. Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol. 2014;20:3100-3111. [PMID: 24696597 DOI: 10.3748/wjg.v20.i12.3100] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 34] [Article Influence: 7.7] [Reference Citation Analysis]
52 Klein PJ, Schmidt CM, Wiesenauer CA, Choi JN, Gage EA, Yip-Schneider MT, Wiebke EA, Wang Y, Omer C, Sebolt-Leopold JS. The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. Neoplasia 2006;8:1-8. [PMID: 16533420 DOI: 10.1593/neo.05373] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
53 Taefi A, Abrishami A, Nasseri-Moghaddam S, Eghtesad B, Sherman M. Surgical resection versus liver transplant for patients with hepatocellular carcinoma. Cochrane Database Syst Rev 2013;:CD006935. [PMID: 23813393 DOI: 10.1002/14651858.CD006935.pub2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
54 Guan YS, La Z, Yang L, He Q, Li P. p53 gene in treatment of hepatic carcinoma: status quo. World J Gastroenterol. 2007;13:985-992. [PMID: 17373730 DOI: 10.3748/wjg.v13.i7.985] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
55 Galun D, Basaric D, Zuvela M, Bulajic P, Bogdanovic A, Bidzic N, Milicevic M. Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol. 2015;7:2274-2291. [PMID: 26380652 DOI: 10.4254/wjh.v7.i20.2274] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
56 Kondo Y, Kimura O, Shimosegawa T. Radiation therapy has been shown to be adaptable for various stages of hepatocellular carcinoma. World J Gastroenterol. 2015;21:94-101. [PMID: 25574082 DOI: 10.3748/wjg.v21.i1.94] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
57 Schraiber LDS, de Mattos AA, Zanotelli ML, Cantisani GPC, Brandão ABM, Marroni CA, Kiss G, Ernani L, Marcon PDS. Alpha-fetoprotein Level Predicts Recurrence After Transplantation in Hepatocellular Carcinoma. Medicine (Baltimore) 2016;95:e2478. [PMID: 26817881 DOI: 10.1097/MD.0000000000002478] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
58 Zeng W, Gouw AS, van den Heuvel MC, Zwiers PJ, Zondervan PE, Poppema S, Zhang N, Platteel I, de Jong KP, Molema G. The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization. Hepatology. 2008;48:1517-1527. [PMID: 18924243 DOI: 10.1002/hep.22490] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
59 Thomas MB, Garrett-Mayer E, Anis M, Anderton K, Bentz T, Edwards A, Brisendine A, Weiss G, Siegel AB, Bendell J, Baron A, Duddalwar V, El-Khoueiry A. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. Oncology 2018;94:329-39. [PMID: 29719302 DOI: 10.1159/000485384] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
60 Zheng Y, Yang H, He L, Mao Y, Zhang H, Zhao H, Du S, Xu Y, Chi T, Xu H, Lu X, Sang X, Zhong S. Reassessment of different criteria for diagnosing post-hepatectomy liver failure: a single-center study of 1683 hepatectomy. Oncotarget 2017;8:89269-77. [PMID: 29179518 DOI: 10.18632/oncotarget.19360] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
61 Zhuang L, Wen T, Xu M, Yang J, Wang W, Wu H, Zeng Y, Yan L, Wei Y, Li B. Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma. Arch Med Sci 2017;13:1383-93. [PMID: 29181069 DOI: 10.5114/aoms.2017.71066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
62 Chen XB, Zheng XB, Cai ZX, Lin XJ, Xu MQ. MicroRNA-203 promotes liver regeneration after partial hepatectomy in cirrhotic rats. J Surg Res. 2017;211:53-63. [PMID: 28501131 DOI: 10.1016/j.jss.2016.11.043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
63 Liu WC, Liu QY. Molecular mechanisms of gender disparity in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2014;20:6252-6261. [PMID: 24876746 DOI: 10.3748/wjg.v20.i20.6252] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
64 Pacella CM, Bizzarri G, Francica G, Forlini G, Petrolati A, Valle D, Anelli V, Bianchini A, Nuntis SD, Pacella S, Rossi Z, Osborn J, Stasi R. Analysis of factors predicting survival in patients with hepatocellular carcinoma treated with percutaneous laser ablation. Journal of Hepatology 2006;44:902-9. [DOI: 10.1016/j.jhep.2006.01.031] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
65 Zhang J, Du J, Liu Q, Zhang Y. Down-regulation of STAT3 expression using vector-based RNA interference promotes apoptosis in Hepatocarcinoma cells. Artif Cells Nanomed Biotechnol 2016;44:1201-5. [PMID: 26134753 DOI: 10.3109/21691401.2015.1029628] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
66 Tang C, Feng W, Qin L, Bao Y. Chinese Herbal Medicine, Jian Pi Li Gan Decoction, Improved Survival of Nonresectable Hepatocellular Cancer After Radiofrequency Ablation: A Retrospective Study. Integr Cancer Ther 2018;17:431-6. [PMID: 28745082 DOI: 10.1177/1534735417722223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
67 Sugimachi K, Sakimura S, Tomokuni A, Uchi R, Hirata H, Komatsu H, Shinden Y, Iguchi T, Eguchi H, Masuda T, Morita K, Shirabe K, Eguchi H, Maehara Y, Mori M, Mimori K. Identification of Recurrence-Related microRNAs from Bone Marrow in Hepatocellular Carcinoma Patients. J Clin Med 2015;4:1600-11. [PMID: 26287250 DOI: 10.3390/jcm4081600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
68 Yoshizumi H, Maruyama H, Okugawa H, Kobayashi S, Akiike T, Yoshikawa M, Ebara M, Yokosuka O, Matsutani S, Kondo F, Kamiyama N. How to characterize non-hypervascular hepatic nodules on contrast-enhanced computed tomography in chronic liver disease: Feasibility of contrast-enhanced ultrasound with a microbubble contrast agent. Journal of Gastroenterology and Hepatology 2008;23:1528-34. [DOI: 10.1111/j.1440-1746.2007.05184.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
69 Bouza C, López-Cuadrado T, Alcázar R, Saz-Parkinson Z, Amate JM. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol. 2009;9:31. [PMID: 19432967 DOI: 10.1186/1471-230x-9-31] [Cited by in Crossref: 101] [Cited by in F6Publishing: 45] [Article Influence: 8.4] [Reference Citation Analysis]
70 Mohammad N, Singh SV, Malvi P, Chaube B, Athavale D, Vanuopadath M, Nair SS, Nair B, Bhat MK. Strategy to enhance efficacy of doxorubicin in solid tumor cells by methyl-β-cyclodextrin: Involvement of p53 and Fas receptor ligand complex. Sci Rep 2015;5:11853. [PMID: 26149967 DOI: 10.1038/srep11853] [Cited by in Crossref: 66] [Cited by in F6Publishing: 49] [Article Influence: 11.0] [Reference Citation Analysis]
71 Hajiev S, Allara E, Motedayеn Aval L, Arizumi T, Bettinger D, Pirisi M, Rimassa L, Pressiani T, Personeni N, Giordano L, Kudo M, Thimme R, Park JW, Taddei TH, Kaplan DE, Ramaswami R, Pinato DJ, Sharma R. Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. Br J Cancer 2021;124:407-13. [PMID: 33071284 DOI: 10.1038/s41416-020-01116-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
72 Choi SI, Yu A, Kim BH, Ko EJ, Park SS, Nam BH, Park JW. A model predicting survival of patients with recurrent or progressive hepatocellular carcinoma: the MORE score. J Gastroenterol Hepatol 2017;32:651-8. [PMID: 27519171 DOI: 10.1111/jgh.13532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
73 Lee JS, Hong EK. Hericium erinaceus enhances doxorubicin-induced apoptosis in human hepatocellular carcinoma cells. Cancer Lett 2010;297:144-54. [PMID: 20554107 DOI: 10.1016/j.canlet.2010.05.006] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 5.9] [Reference Citation Analysis]
74 Gallo C, De Maio E, Di Maio M, Signoriello G, Daniele B, Pignata S, Annunziata A, Perrone F; CLIP (Cancer of the Liver Italian Programme) Investigators. Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma. BMC Cancer 2006;6:196. [PMID: 16863588 DOI: 10.1186/1471-2407-6-196] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
75 von Felden J, Schulze K, Krech T, Ewald F, Nashan B, Pantel K, Lohse AW, Riethdorf S, Wege H. Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection. Oncotarget. 2017;8:89978-89987. [PMID: 29163804 DOI: 10.18632/oncotarget.21208] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
76 Zheng Q, Yang Q, Zhou J, Gu X, Zhou H, Dong X, Zhu H, Chen Z. Immune signature-based hepatocellular carcinoma subtypes may provide novel insights into therapy and prognosis predictions. Cancer Cell Int 2021;21:330. [PMID: 34193146 DOI: 10.1186/s12935-021-02033-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Guiu B, Colin C, Cercueil J, Loffroy R, Guiu S, Ferrant E, Jouve J, Bonnetain F, Boulin M, Ghiringhelli F, Minello A, Hillon P, Bedenne L, Krause D, Chauffert B. Pilot Study of Transarterial Chemoembolization With Pirarubicin and Amiodarone for Unresectable Hepatocellular Carcinoma. American Journal of Clinical Oncology 2009;32:238-44. [DOI: 10.1097/coc.0b013e3181845529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
78 Gusani NJ, Jiang Y, Kimchi ET, Staveley-oʼcarroll KF, Cheng H, Ajani JA. New Pharmacological Developments in the Treatment of Hepatocellular Cancer: . Drugs 2009;69:2533-40. [DOI: 10.2165/11530870-000000000-00000] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
79 Ohtsubo K, Watanabe H, Tsuchiyama T, Mouri H, Yamaguchi Y, Motoo Y, Okai T, Sanada J, Matsui O, Kitamura T, Fujiki R, Tokuuye K, Sawabu N. Advanced hepatocellular carcinoma treated effectively with irinotecan via hepatic arterial infusion followed by proton beam therapy. J Infect Chemother 2009;15:316-21. [PMID: 19856070 DOI: 10.1007/s10156-009-0702-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
80 Ito R, Ishii Y, Wakiyama S, Shiba H, Fujioka S, Misawa T, Ishida Y, Hano H, Yanaga K. Prognostic significance of receptor for advanced glycation end products expression in hepatocellular carcinoma after hepatectomy. J Surg Res. 2014;192:503-508. [PMID: 25043528 DOI: 10.1016/j.jss.2014.06.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
81 Shaker MK, Abdella HM, Khalifa MO, El Dorry AK. Epidemiological characteristics of hepatocellular carcinoma in Egypt: a retrospective analysis of 1313 cases. Liver Int. 2013;33:1601-1606. [PMID: 23714212 DOI: 10.1111/liv.12209] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
82 Rempp H, Clasen S, Pereira PL. Image-based monitoring of magnetic resonance-guided thermoablative therapies for liver tumors. Cardiovasc Intervent Radiol. 2012;35:1281-1294. [PMID: 21785888 DOI: 10.1007/s00270-011-0227-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
83 Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer. 2008;113:995-1003. [PMID: 18615601 DOI: 10.1002/cncr.23684] [Cited by in Crossref: 109] [Cited by in F6Publishing: 91] [Article Influence: 8.4] [Reference Citation Analysis]
84 Han G, Yang J, Shao G, Teng G, Wang M, Yang J, Liu Z, Feng G, Yang R, Lu L. Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial. Future Oncol. 2013;9:403-410. [PMID: 23469975 DOI: 10.2217/fon.13.11] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
85 Coban Z, Barton MC. Integrative genomics: liver regeneration and hepatocellular carcinoma. J Cell Biochem 2012;113:2179-84. [PMID: 22345090 DOI: 10.1002/jcb.24104] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
86 Syha R, Ketelsen D, Heller S, Schmehl J, Mangold S, Heuschmid M, Springer F, Claussen CD, Brechtel K. Hepatocellular carcinoma: initial tumour response after short-term and long-interval chemoembolization with drug-eluting beads using modified RECIST. Eur J Gastroenterol Hepatol 2012;24:1325-32. [PMID: 22872074 DOI: 10.1097/MEG.0b013e32835724bc] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
87 Bertelli R, Neri F, Tsivian M, Ruhrman N, Cavallari G, Beltempo P, Puviani L, DeVinci C, Pizza G, Nardo B. Endolymphatic immunotherapy in inoperable hepatocellular carcinoma. Transplant Proc. 2008;40:1913-1915. [PMID: 18675087 DOI: 10.1016/j.transproceed.2008.05.049] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
88 Lischalk JW, Repka MC, Unger K. Radiation therapy for hepatobiliary malignancies. J Gastrointest Oncol. 2017;8:279-292. [PMID: 28480067 DOI: 10.21037/jgo.2016.08.02] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
89 Takeishi K, Shirabe K, Muto J, Toshima T, Taketomi A, Maehara Y. Clinicopathological features and outcomes of young patients with hepatocellular carcinoma after hepatectomy. World J Surg 2011;35:1063-71. [PMID: 21380583 DOI: 10.1007/s00268-011-1017-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
90 Yan F, Wang M, Li J, Cheng H, Su J, Wang X, Wu H, Xia L, Li X, Chang HC, Li Q. Gambogenic acid induced mitochondrial-dependent apoptosis and referred to phospho-Erk1/2 and phospho-p38 MAPK in human hepatoma HepG2 cells. Environ Toxicol Pharmacol 2012;33:181-90. [PMID: 22222560 DOI: 10.1016/j.etap.2011.12.006] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
91 Myung SJ, Yoon J, Yu SJ. STAT3 & Cytochrome P450 2C9: A novel signaling pathway in liver cancer stem cells. Biomedicine & Pharmacotherapy 2012;66:612-6. [DOI: 10.1016/j.biopha.2012.08.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
92 Berretta M, Di Benedetto F, Dal Maso L, Cacopardo B, Nasti G, Facchini G, Bearz A, Spina M, Garlassi E, De Re V, Fiorica F, Lleshi A, Tirelli U. Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. Anti-Cancer Drugs 2013;24:212-8. [DOI: 10.1097/cad.0b013e32835c032f] [Cited by in Crossref: 26] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
93 Xu J, Qi F, Xu G, Chen G, Huang M, Zhang J. Adjuvant interferon therapy after surgical treatment for hepatitis B/C virus-related hepatocellular carcinoma: A meta-analysis: Meta-analysis of adjuvant IFN after HCC. Hepatol Res 2014;44:209-17. [DOI: 10.1111/hepr.12109] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
94 Li JH, Xie XY, Zhang L, Le F, Ge NL, Li LX, Gan YH, Chen Y, Zhang JB, Xue TC, Chen RX, Xia JL, Zhang BH, Ye SL, Wang YH, Ren ZG. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. World J Gastroenterol 2015;21:3970-7. [PMID: 25852283 DOI: 10.3748/wjg.v21.i13.3970] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
95 Ziober AF, D'Alessandro L, Ziober BL. Is gene expression profiling of head and neck cancers ready for the clinic? Biomark Med 2010;4:571-80. [PMID: 20701444 DOI: 10.2217/bmm.10.71] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
96 Hu HT, Kim JH, Lee LS, Kim KA, Ko GY, Yoon HK, Sung KB, Gwon DI, Shin JH, Song HY. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort. J Vasc Interv Radiol. 2011;22:917-923. [PMID: 21571545 DOI: 10.1016/j.jvir.2011.03.005] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 6.0] [Reference Citation Analysis]
97 Ishizaki Y, Kawasaki S. The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future). J Gastroenterol 2008;43:18-26. [DOI: 10.1007/s00535-007-2141-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
98 Hou YF, Wei YG, Yang JY, Wen TF, Xu MQ, Yan LN, Li B. Combined hepatectomy and radiofrequency ablation versus TACE in improving survival of patients with unresectable BCLC stage B HCC. Hepatobiliary Pancreat Dis Int. 2016;15:378-385. [PMID: 27498577 DOI: 10.1016/s1499-3872(16)60089-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
99 de Graaf W, Veteläinen RL, de Bruin K, van Vliet AK, van Gulik TM, Bennink RJ. 99m Tc-GSA Scintigraphy with SPECT for Assessment of Hepatic Function and Functional Volume During Liver Regeneration in a Rat Model of Partial Hepatectomy. J Nucl Med 2007;49:122-8. [DOI: 10.2967/jnumed.107.044255] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
100 Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Matejka J, Stauber R, Buder R, Grünberger B, Schöniger-Hekele M, Müller C, Peck-Radosavljevic M. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011;34:949-59. [PMID: 21883324 DOI: 10.1111/j.1365-2036.2011.04823.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 5.9] [Reference Citation Analysis]
101 Wang J, Xu L, Zeng W, Hu P, Zeng M, Rabkin SD, Liu R. Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta. Cancer Cell Int 2014;14:83. [PMID: 25360068 DOI: 10.1186/s12935-014-0083-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
102 Choi AR, Jee Jo M, Jung MJ, Sik Kim H, Yoon S. Selenate specifically sensitizes drug-resistant cancer cells by increasing apoptosis via G2 phase cell cycle arrest without P-GP inhibition. Eur J Pharmacol 2015;764:63-9. [PMID: 26134503 DOI: 10.1016/j.ejphar.2015.06.046] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
103 Wang Q, Zheng B, Ma B, Yang K; Cochrane Hepato-Biliary Group. Anterior approach versus conventional liver resection for hepatocellular carcinoma. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd010545] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
104 Yan J, Fan Z, Wu X, Xu M, Jiang J, Tan C, Wu W, Wei X, Zhou J. Circulating tumor cells are correlated with disease progression and treatment response in an orthotopic hepatocellular carcinoma model. Cytometry A. 2015;87:1020-1028. [PMID: 26355643 DOI: 10.1002/cyto.a.22782] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
105 Pinter M, Wichlas M, Schmid K, Plank C, Müller C, Wrba F, Peck-radosavljevic M. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial: . European Journal of Gastroenterology & Hepatology 2008;20:1012-9. [DOI: 10.1097/meg.0b013e3283036740] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
106 Liu F, Zhang Y, Peng Z, Gao H, Xu L, Chen M. High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. J Transl Med. 2012;10:135. [PMID: 22747650 DOI: 10.1186/1479-5876-10-135] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.2] [Reference Citation Analysis]
107 Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer. 2010;116:1305-1314. [PMID: 20066715 DOI: 10.1002/cncr.24884] [Cited by in Crossref: 120] [Cited by in F6Publishing: 105] [Article Influence: 10.9] [Reference Citation Analysis]
108 Brito AF, Abrantes AM, Tralhão JG, Botelho MF. Targeting Hepatocellular Carcinoma: What did we Discover so Far? Oncol Rev 2016;10:302. [PMID: 27994769 DOI: 10.4081/oncol.2016.302] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
109 Venook AP, Papandreou C, Furuse J, Ladrón de Guevara L. The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective. The Oncologist 2010;15:5-13. [DOI: 10.1634/theoncologist.2010-s4-05] [Cited by in Crossref: 575] [Cited by in F6Publishing: 308] [Article Influence: 52.3] [Reference Citation Analysis]
110 Amesur NB, Zajko AB. Interventional radiology in liver transplantation. Liver Transpl. 2006;12:330-351. [PMID: 16498660 DOI: 10.1002/lt.20731] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
111 Zhang Z, Zhang J, Zhang Y, Xing J, Yu Z. Vaccinia virus expressing IL-37 promotes antitumor immune responses in hepatocellular carcinoma. Cell Biochem Funct 2019;37:618-24. [PMID: 31710117 DOI: 10.1002/cbf.3438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
112 Jun BG, Lee WC, Jang JY, Jeong SW, Chang Y, Lee SH, Kim YD, Kim SG, Cheon GJ, Kim YS, Kim HS, Jin SY. Relation of fibroblast growth factor receptor 2 expression to hepatocellular carcinoma recurrence after liver resection. PLoS One 2020;15:e0227440. [PMID: 31940413 DOI: 10.1371/journal.pone.0227440] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
113 Komatsu Y, Waku T, Iwasaki N, Ono W, Yamaguchi C, Yanagisawa J. Global analysis of DNA methylation in early-stage liver fibrosis. BMC Med Genomics. 2012;5:5. [PMID: 22281153 DOI: 10.1186/1755-8794-5-5] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 6.7] [Reference Citation Analysis]
114 Abrishami A, Nasseri-moghaddam S, Eghtesad B, Sherman M, Abrishami A. Surgical resection for hepatocellular carcinoma. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd006935] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
115 Maiwald B, Lobsien D, Kahn T, Stumpp P. Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma? PLoS One. 2014;9:e111935. [PMID: 25375778 DOI: 10.1371/journal.pone.0111935] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
116 Syha R, Grözinger G, Grosse U, Maurer M, Zender L, Horger M, Nikolaou K, Ketelsen D. Parenchymal Blood Volume Assessed by C-Arm-Based Computed Tomography in Immediate Posttreatment Evaluation of Drug-Eluting Bead Transarterial Chemoembolization in Hepatocellular Carcinoma. Invest Radiol. 2016;51:121-126. [PMID: 26488373 DOI: 10.1097/rli.0000000000000215] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
117 Iwasa S, Ikeda M, Okusaka T, Ueno H, Morizane C, Nakachi K, Mitsunaga S, Kondo S, Hagihara A, Shimizu S. Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Jpn J Clin Oncol. 2011;41:770-775. [PMID: 21459893 DOI: 10.1093/jjco/hyr037] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
118 Ignee A, Jedrejczyk M, Schuessler G, Jakubowski W, Dietrich CF. Quantitative contrast enhanced ultrasound of the liver for time intensity curves-Reliability and potential sources of errors. Eur J Radiol. 2010;73:153-158. [PMID: 19157739 DOI: 10.1016/j.ejrad.2008.10.016] [Cited by in Crossref: 65] [Cited by in F6Publishing: 48] [Article Influence: 5.4] [Reference Citation Analysis]
119 Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, Fan ST. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol. 2007;5:1100-1108. [PMID: 17627902 DOI: 10.1016/j.cgh.2007.04.021] [Cited by in Crossref: 185] [Cited by in F6Publishing: 158] [Article Influence: 13.2] [Reference Citation Analysis]
120 Artinyan A, Nelson R, Soriano P, Chung V, Retseck J, Reynolds J, Marx H, Kim J, Wagman L. Treatment response to transcatheter arterial embolization and chemoembolization in primary and metastatic tumors of the liver. HPB (Oxford). 2008;10:396-404. [PMID: 19088924 DOI: 10.1080/13651820802356564] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
121 Qiao Y, Pei Y, Luo M, Rajasekaran M, Hui KM, Chen J. Cytokinesis regulators as potential diagnostic and therapeutic biomarkers for human hepatocellular carcinoma. Exp Biol Med (Maywood) 2021;246:1343-54. [PMID: 33899543 DOI: 10.1177/15353702211008380] [Reference Citation Analysis]
122 Ruan DY, Lin ZX, Wang TT, Zhao H, Wu DH, Chen J, Dong M, Lin Q, Wu XY, Li Y. Nomogram for preoperative estimation of long-term survival of patients who underwent curative resection with hepatocellular carcinoma beyond Barcelona clinic liver cancer stage A1. Oncotarget 2016;7:61378-89. [PMID: 27542216 DOI: 10.18632/oncotarget.11358] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
123 Tsurusaki M, Murakami T. Surgical and Locoregional Therapy of HCC: TACE. Liver Cancer 2015;4:165-75. [PMID: 26675172 DOI: 10.1159/000367739] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 8.2] [Reference Citation Analysis]
124 Méndez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, Nuyttens JJ, Brandwijk RP, Verhoef C, Ijzermans JN. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol. 2006;45:831-837. [PMID: 16982547 DOI: 10.1080/02841860600897934] [Cited by in Crossref: 348] [Cited by in F6Publishing: 261] [Article Influence: 24.9] [Reference Citation Analysis]
125 Zeeneldin AA, Salem SE, Darwish AD, El-Gammal MM, Hussein MM, Saadeldin M. Untreated hepatocellular carcinoma in Egypt: outcome and prognostic factors. J Hepatocell Carcinoma 2015;2:3-9. [PMID: 27508189 DOI: 10.2147/JHC.S73828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
126 Ma S, Wu J, Wu J, Wei Y, Zhang L, Ning Q, Hu D. Relationship between HLA-DRB1 allele polymorphisms and familial aggregations of hepatocellular carcinoma. Curr Oncol 2016;23:e1-7. [PMID: 26966407 DOI: 10.3747/co.23.2839] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
127 shen J, Li C, Wen T, Yan L, Li B, Wang W, Yang J, Xu M, wen J. Transplantation versus hepatectomy for HCC beyond the Milan criteria: A propensity score analysis. International Journal of Surgery 2017;44:33-42. [DOI: 10.1016/j.ijsu.2017.05.034] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
128 Rempp H, Boss A, Helmberger T, Pereira P. The current role of minimally invasive therapies in the management of liver tumors. Abdom Imaging. 2011;36:635-647. [PMID: 21562884 DOI: 10.1007/s00261-011-9749-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
129 Kim KM, Kim JH, Park IS, Ko GY, Yoon HK, Sung KB, Lim YS, Lee HC, Chung YH, Lee YS. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol. 2009;24:806-814. [PMID: 19207681 DOI: 10.1111/j.1440-1746.2008.05728.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 88] [Article Influence: 8.2] [Reference Citation Analysis]
130 Hebbar M, Ernst O, Cattan S, Dominguez S, Oprea C, Mathurin P, Triboulet J, Paris J, Pruvot F. Phase II Trial of Docetaxel Therapy in Patients with Advanced Hepatocellular Carcinoma. Oncology 2006;70:154-8. [DOI: 10.1159/000093007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
131 Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011;47:2117-2127. [PMID: 21664811 DOI: 10.1016/j.ejca.2011.05.007] [Cited by in Crossref: 304] [Cited by in F6Publishing: 303] [Article Influence: 30.4] [Reference Citation Analysis]
132 Ruggieri A, Barbati C, Malorni W. Cellular and molecular mechanisms involved in hepatocellular carcinoma gender disparity. Int J Cancer. 2010;127:499-504. [PMID: 20201099 DOI: 10.1002/ijc.25298] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 4.8] [Reference Citation Analysis]
133 Dang Q, Shao B, Zhou Q, Chen C, Guo Y, Wang G, Liu J, Kan Q, Yuan W, Sun Z. RNA N 6-Methyladenosine in Cancer Metastasis: Roles, Mechanisms, and Applications. Front Oncol 2021;11:681781. [PMID: 34211849 DOI: 10.3389/fonc.2021.681781] [Reference Citation Analysis]
134 Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Fox R, Yeo W, Mo F, Lai P, Chan SL, Tada T, Toyoda H, Kumada T. Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. Br J Cancer. 2017;116:441-447. [PMID: 28081537 DOI: 10.1038/bjc.2016.422] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
135 Wu J, Du J, Liu L, Li Q, Rong W, Wang L, Wang Y, Zang M, Wu Z, Zhang Y. Elevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy. PLoS One. 2012;7:e50035. [PMID: 23227158 DOI: 10.1371/journal.pone.0050035] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
136 Cui J, Yu Y, Lu GF, Liu C, Liu X, Xu YX, Zheng PY. Overexpression of ARK5 is associated with poor prognosis in hepatocellular carcinoma. Tumour Biol 2013;34:1913-8. [PMID: 23516026 DOI: 10.1007/s13277-013-0735-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
137 Meléndez-Alafort L, Nadali A, Zangoni E, Banzato A, Rondina M, Rosato A, Mazzi U. Biokinetic and dosimetric studies of 188Re-hyaluronic acid: a new radiopharmaceutical for treatment of hepatocellular carcinoma. Nucl Med Biol 2009;36:693-701. [PMID: 19647176 DOI: 10.1016/j.nucmedbio.2009.04.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
138 Hata M, Tokuuye K, Sugahara S, Fukumitsu N, Hashimoto T, Ohnishi K, Nemoto K, Ohara K, Matsuzaki Y, Akine Y. Proton beam therapy for hepatocellular carcinoma with limited treatment options. Cancer 2006;107:591-8. [PMID: 16804931 DOI: 10.1002/cncr.22039] [Cited by in Crossref: 54] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
139 Kim EY, Choi D, Lim do H, Lee WJ, Yoo BC, Paik SW. Change in contrast enhancement of HCC on 1-month follow-up CT after local radiotherapy: an early predictor of final treatment response. Eur J Radiol. 2009;72:440-446. [PMID: 18819767 DOI: 10.1016/j.ejrad.2008.07.036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
140 Schumacher G, Gebauer B. Transarterial chemoembolization for hepatocellular carcinoma with portal vein invasion: a helpful palliative approach. J Gastroenterol Hepatol 2009;24:1317-9. [PMID: 19702898 DOI: 10.1111/j.1440-1746.2009.05976.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
141 Massarweh NN, Park JO, Farjah F, Yeung RS, Symons RG, Vaughan TL, Baldwin LM, Flum DR. Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg. 2010;210:441-448. [PMID: 20347736 DOI: 10.1016/j.jamcollsurg.2009.12.026] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
142 Li S, Beheshti M, Peck-Radosavljevic M, Oezer S, Grumbeck E, Schmid M, Hamilton G, Kapiotis S, Dudczak R, Kletter K. Comparison of (11)C-acetate positron emission tomography and (67)Gallium citrate scintigraphy in patients with hepatocellular carcinoma. Liver Int 2006;26:920-7. [PMID: 16953831 DOI: 10.1111/j.1478-3231.2006.01335.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
143 Ye X, Guo Y, Zhang Q, Chen W, Hua X, Liu W, Yang Y, Chen G. βKlotho suppresses tumor growth in hepatocellular carcinoma by regulating Akt/GSK-3β/cyclin D1 signaling pathway. PLoS One 2013;8:e55615. [PMID: 23383245 DOI: 10.1371/journal.pone.0055615] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
144 Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Tokita M, Abei M, Shoda J, Matsuzaki Y, Thono E, Tsuboi K, Tokuuye K. Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol. 2009;185:782-788. [PMID: 20013087 DOI: 10.1007/s00066-009-2020-x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 59] [Article Influence: 6.6] [Reference Citation Analysis]
145 Taflin H, Hafström L, Holmberg E, Castedal M, Lindnér P. The impact of increased immigration to Sweden on the incidence and treatment of patients with HCC and underlying liver disease. Scandinavian Journal of Gastroenterology 2019;54:746-52. [DOI: 10.1080/00365521.2019.1627580] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
146 Azab M, Zaki S, El-Shetey AG, Abdel-Moty MF, Alnoomani NM, Gomaa AA, Abdel-Fatah S, Mohiy S, Atia F. Radiofrequency ablation combined with percutaneous ethanol injection in patients with hepatocellular carcinoma. Arab J Gastroenterol. 2011;12:113-118. [PMID: 22055587 DOI: 10.1016/j.ajg.2011.07.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
147 Erinjeri JP, Deodhar A, Thornton RH, Allen PJ, Getrajdman GI, Brown KT, Sofocleous CT, Reidy DL. Resolution of hepatic encephalopathy following hepatic artery embolization in a patient with well-differentiated neuroendocrine tumor metastatic to the liver. Cardiovasc Intervent Radiol 2010;33:610-4. [PMID: 19756861 DOI: 10.1007/s00270-009-9698-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
148 Kao JT, Feng CL, Yu CJ, Tsai SM, Hsu PN, Chen YL, Wu YY. IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study. BMC Gastroenterol 2015;15:50. [PMID: 25908103 DOI: 10.1186/s12876-015-0283-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
149 Carr BI, Carroll S, Muszbek N, Gondek K. Economic evaluation of sorafenib in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 2010;25:1739-1746. [PMID: 21039835 DOI: 10.1111/j.1440-1746.2010.06404.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
150 Petrini I, Lencioni M, Ricasoli M, Iannopollo M, Orlandini C, Oliveri F, Bartolozzi C, Ricci S. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2012;69:773-780. [PMID: 22033636 DOI: 10.1007/s00280-011-1753-2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
151 Al-alem I, Pillai K, Akhter J, Chua TC, Morris DL. Heat Sink Phenomenon of Bipolar and Monopolar Radiofrequency Ablation Observed Using Polypropylene Tubes for Vessel Simulation. Surg Innov 2014;21:269-76. [DOI: 10.1177/1553350613505713] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
152 Hata M, Tokuuye K, Sugahara S, Tohno E, Nakayama H, Fukumitsu N, Mizumoto M, Abei M, Shoda J, Minami M, Akine Y. Proton Beam Therapy for Aged Patients With Hepatocellular Carcinoma. International Journal of Radiation Oncology*Biology*Physics 2007;69:805-12. [DOI: 10.1016/j.ijrobp.2007.04.016] [Cited by in Crossref: 44] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
153 Saidi RF, Shah SA, Rawson AP, Grossman S, Piperdi B, Bozorgzadeh A. Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience. Transplant Proc. 2010;42:4582-4584. [PMID: 21168742 DOI: 10.1016/j.transproceed.2010.09.147] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
154 Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25:2586-2593. [PMID: 17577038 DOI: 10.1200/jco.2006.09.4565] [Cited by in Crossref: 719] [Cited by in F6Publishing: 375] [Article Influence: 51.4] [Reference Citation Analysis]
155 Rempp H, Loh H, Hoffmann R, Rothgang E, Pan L, Claussen CD, Clasen S. Liver lesion conspicuity during real-time MR-guided radiofrequency applicator placement using spoiled gradient echo and balanced steady-state free precession imaging. J Magn Reson Imaging. 2014;40:432-439. [PMID: 24677447 DOI: 10.1002/jmri.24371] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
156 Lanton T, Shriki A, Nechemia-Arbely Y, Abramovitch R, Levkovitch O, Adar R, Rosenberg N, Paldor M, Goldenberg D, Sonnenblick A, Peled A, Rose-John S, Galun E, Axelrod JH. Interleukin 6-dependent genomic instability heralds accelerated carcinogenesis following liver regeneration on a background of chronic hepatitis. Hepatology 2017;65:1600-11. [PMID: 28027584 DOI: 10.1002/hep.29004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
157 Luk JM, Wong K. MONOCLONAL ANTIBODIES AS TARGETING AND THERAPEUTIC AGENTS: PROSPECTS FOR LIVER TRANSPLANTATION, HEPATITIS AND HEPATOCELLULAR CARCINOMA. Clin Exp Pharmacol Physiol 2006;33:482-8. [DOI: 10.1111/j.1440-1681.2006.04396.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
158 Wang W, Iyer NG, Tay HT, Wu Y, Lim TK, Zheng L, Song IC, Kwoh CK, Huynh H, Tan PO, Chow PK. Microarray profiling shows distinct differences between primary tumors and commonly used preclinical models in hepatocellular carcinoma. BMC Cancer 2015;15:828. [PMID: 26520397 DOI: 10.1186/s12885-015-1814-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
159 Herbold T, Wahba R, Bangard C, Demir M, Drebber U, Stippel DL. The laparoscopic approach for radiofrequency ablation of hepatocellular carcinoma—indication, technique and results. Langenbecks Arch Surg 2013;398:47-53. [DOI: 10.1007/s00423-012-1018-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
160 Yang H, Nie Y, Li Y, Wan YJ. Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells. Exp Biol Med (Maywood) 2010;235:32-9. [PMID: 20404016 DOI: 10.1258/ebm.2009.009252] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
161 Sanda M, Benicky J, Wu J, Wang Y, Makambi K, Ahn J, Smith CI, Zhao P, Zhang L, Goldman R. Increased sialylation of site specific O-glycoforms of hemopexin in liver disease. Clin Proteomics 2016;13:24. [PMID: 27688741 DOI: 10.1186/s12014-016-9125-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
162 Zahavi T, Lanton T, Divon MS, Salmon A, Peretz T, Galun E, Axelrod JH, Sonnenblick A. Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model. Oncotarget 2016;7:4860-70. [PMID: 26695439 DOI: 10.18632/oncotarget.6638] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
163 Daher S, Massarwa M, Benson AA, Khoury T. Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review. J Clin Transl Hepatol. 2018;6:69-78. [PMID: 29607307 DOI: 10.14218/jcth.2017.00031] [Cited by in Crossref: 97] [Cited by in F6Publishing: 59] [Article Influence: 24.3] [Reference Citation Analysis]
164 Xu M, Qian G, Xie F, Shi C, Yan L, Yu L, Zheng T, Wei L, Yang J. Expression of epithelial cell adhesion molecule associated with elevated ductular reactions in hepatocellar carcinoma. Clinics and Research in Hepatology and Gastroenterology 2014;38:699-705. [DOI: 10.1016/j.clinre.2014.04.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
165 Kanzaki H, Nouso K, Miyahara K, Kajikawa N, Kobayashi S, Sakakihara I, Iwadow S, Uematsu S, Okamoto R, Shiraga K, Mizuno M, Araki Y. A case of hepatocellular carcinoma with skin injury of the upper abdominal wall after transcatheter arterial chemoembolization: a case report. Cases J 2009;2:7197. [PMID: 19918514 DOI: 10.4076/1757-1626-2-7197] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
166 Romano O, Truant S, Sergent-Baudson G, Comet B, Pruvot FR, Hebbar M. Docetaxel therapy for advanced hepatocellular carcinoma developed in healthy liver: report of three cases. J Chemother 2008;20:518-20. [PMID: 18676236 DOI: 10.1179/joc.2008.20.4.518] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
167 Kim Y, Ejaz A, Tayal A, Spolverato G, Bridges JF, Anders RA, Pawlik TM. Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years. Cancer 2014;120:3058-65. [PMID: 24917245 DOI: 10.1002/cncr.28843] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.7] [Reference Citation Analysis]
168 Imam MH, Silveira MG, Sinakos E, Gossard AA, Jorgensen R, Keach J, Decook AC, Lindor KD. Long-term Outcomes of Patients With Primary Biliary Cirrhosis and Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology 2012;10:182-5. [DOI: 10.1016/j.cgh.2011.09.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
169 Hsieh CB, Chou SJ, Shih ML, Chu HC, Chu CH, Yu JC, Yao NS. Preliminary experience with gemcitabine and cisplatin adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 2008;34:906-10. [PMID: 18166289 DOI: 10.1016/j.ejso.2007.11.014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
170 Groeschl RT, Hong JC, Christians KK, Turaga KK, Tsai S, Pilgrim CH, Gamblin TC. Viral status at the time of liver transplantation for hepatocellular carcinoma: a modern predictor of longterm survival. HPB (Oxford) 2013;15:794-802. [PMID: 23782341 DOI: 10.1111/hpb.12134] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
171 Gupta H, Youn GS, Shin MJ, Suk KT. Role of Gut Microbiota in Hepatocarcinogenesis. Microorganisms. 2019;7:pii: E121. [PMID: 31060311 DOI: 10.3390/microorganisms7050121] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 19.5] [Reference Citation Analysis]
172 Nouso K, Ito Y, Kuwaki K, Kobayashi Y, Nakamura S, Ohashi Y, Yamamoto K. Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. Br J Cancer. 2008;98:1161-1165. [PMID: 18349849 DOI: 10.1038/sj.bjc.6604282] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
173 Scartozzi M, Baroni GS, Faloppi L, Paolo MD, Pierantoni C, Candelari R, Berardi R, Antognoli S, Mincarelli C, Risaliti A. Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. J Exp Clin Cancer Res. 2010;29:164. [PMID: 21159184 DOI: 10.1186/1756-9966-29-164] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
174 Sugimachi K, Kinjo N, Ikebe M, Yamashita N, Kajiwara E, Mimori K, Higashi H. Significance of hepatic resection for hepatocellular carcinoma with sustained virological response to interferon therapy for chronic hepatitis C. Hepatol Res 2013;43:605-9. [PMID: 23145902 DOI: 10.1111/j.1872-034X.2012.01112.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
175 Fan C, Zheng W, Fu X, Li X, Wong YS, Chen T. Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling. Oncotarget 2014;5:2853-63. [PMID: 24797310 DOI: 10.18632/oncotarget.1854] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 10.3] [Reference Citation Analysis]
176 Zhu S, Huang X, Zhang K, Tan W, Lin Z, He Q, Chen Y, Shang C. Low expression of long noncoding RNA CTC-297N7.9 predicts poor prognosis in patients with hepatocellular carcinoma. Cancer Med 2019;8:7679-92. [PMID: 31674731 DOI: 10.1002/cam4.2618] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
177 Cabibbo G, Rolle E, De Giorgio M, Genco C, Pressiani T, Spada F, Sacco R. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. Expert Rev Anticancer Ther. 2011;11:1807-1816. [PMID: 22049974 DOI: 10.1586/era.11.139] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
178 Hoffmann R, Jakobs TF, Reiser MF. Identification of Candidates and Selection Criteria. In: Bilbao JI, Reiser MF, editors. Liver Radioembolization with 90Y Microspheres. Berlin: Springer Berlin Heidelberg; 2008. pp. 11-4. [DOI: 10.1007/978-3-540-35423-9_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
179 Goldman R, Ressom HW, Abdel-Hamid M, Goldman L, Wang A, Varghese RS, An Y, Loffredo CA, Drake SK, Eissa SA. Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum. Carcinogenesis. 2007;28:2149-2153. [PMID: 17724376 DOI: 10.1093/carcin/bgm177] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
180 Cao M, Xu Y, Youn JI, Cabrera R, Zhang X, Gabrilovich D, Nelson DR, Liu C. Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Lab Invest. 2011;91:598-608. [PMID: 21321535 DOI: 10.1038/labinvest.2010.205] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 7.9] [Reference Citation Analysis]
181 Ohri N, Dawson LA, Krishnan S, Seong J, Cheng JC, Sarin SK, Kinkhabwala M, Ahmed MM, Vikram B, Coleman CN, Guha C. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. J Natl Cancer Inst. 2016;108. [PMID: 27377923 DOI: 10.1093/jnci/djw133] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 7.2] [Reference Citation Analysis]
182 Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34. [PMID: 19095497 DOI: 10.1016/s1470-2045(08)70285-7] [Cited by in Crossref: 3367] [Cited by in F6Publishing: 1718] [Article Influence: 259.0] [Reference Citation Analysis]
183 Xie G, Meng T, Luo Y, Liu Z. SKF-LDA: Similarity Kernel Fusion for Predicting lncRNA-Disease Association. Mol Ther Nucleic Acids 2019;18:45-55. [PMID: 31514111 DOI: 10.1016/j.omtn.2019.07.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
184 Tang CW, Zhu M, Feng WM, Bao Y, Zheng YY. Chinese herbal medicine, Jianpi Ligan decoction, improves prognosis of unresectable hepatocellular carcinoma after transarterial chemoembolization: a retrospective study. Drug Des Devel Ther 2016;10:2461-6. [PMID: 27536066 DOI: 10.2147/DDDT.S113295] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
185 Nishikawa H, Osaki Y, Iguchi E, Koshikawa Y, Ako S, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A. The effect of long-term supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation. J Clin Gastroenterol. 2013;47:359-366. [PMID: 23090049 DOI: 10.1097/mcg.0b013e31826be9ad] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 3.1] [Reference Citation Analysis]
186 Jegal ME, Jung SY, Han YS, Kim YJ. C-terminal truncated HBx reduces doxorubicin cytotoxicity via ABCB1 upregulation in Huh-7 hepatocellular carcinoma cells. BMB Rep 2019;52:330-5. [PMID: 30982500 [PMID: 30982500 DOI: 10.5483/bmbrep.2019.52.5.312] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
187 Amini N, Ejaz A, Spolverato G, Maithel SK, Kim Y, Pawlik TM. Management of Lymph Nodes During Resection of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Systematic Review. J Gastrointest Surg 2014;18:2136-48. [DOI: 10.1007/s11605-014-2667-1] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
188 Kang SH, Park SW. Symptomatic post-discectomy pseudocyst after endoscopic lumbar discectomy. J Korean Neurosurg Soc. 2011;49:31-36. [PMID: 21494360 DOI: 10.3340/jkns.2011.49.1.31] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
189 Efremidis SC, Hytiroglou P, Matsui O. Enhancement patterns and signal-intensity characteristics of small hepatocellular carcinoma in cirrhosis: pathologic basis and diagnostic challenges. Eur Radiol. 2007;17:2969-2982. [PMID: 17618439 DOI: 10.1007/s00330-007-0705-z] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
190 Goldman R, Ressom HW, Varghese RS, Goldman L, Bascug G, Loffredo CA, Abdel-Hamid M, Gouda I, Ezzat S, Kyselova Z. Detection of hepatocellular carcinoma using glycomic analysis. Clin Cancer Res. 2009;15:1808-1813. [PMID: 19223512 DOI: 10.1158/1078-0432.ccr-07-5261] [Cited by in Crossref: 108] [Cited by in F6Publishing: 62] [Article Influence: 9.0] [Reference Citation Analysis]
191 Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Plank C, Peck-Radosavljevic M. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist. 2009;14:70-76. [PMID: 19144684 DOI: 10.1634/theoncologist.2008-0191] [Cited by in Crossref: 127] [Cited by in F6Publishing: 119] [Article Influence: 10.6] [Reference Citation Analysis]
192 Harlan LC, Parsons HM, Wiggins CL, Stevens JL, Patt YZ. Treatment of hepatocellular carcinoma in the community: disparities in standard therapy. Liver Cancer. 2015;4:70-83. [PMID: 26020030 DOI: 10.1159/000367729] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
193 Tsuda Y, Fukui H, Asai A, Fukunishi S, Miyaji K, Fujiwara S, Teramura K, Fukuda A, Higuchi K. An immunosuppressive subtype of neutrophils identified in patients with hepatocellular carcinoma. J Clin Biochem Nutr 2012;51:204-12. [PMID: 23170048 DOI: 10.3164/jcbn.12-32] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
194 Callstrom MR, Charboneau JW. Technologies for ablation of hepatocellular carcinoma. Gastroenterology. 2008;134:1831-1835. [PMID: 18486619 DOI: 10.1053/j.gastro.2008.05.022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
195 Goyal K, Einstein D, Yao M, Kunos C, Barton F, Singh D, Siegel C, Stulberg J, Sanabria J. Cyberknife stereotactic body radiation therapy for nonresectable tumors of the liver: preliminary results. HPB Surg. 2010;2010:Epub 2010 Jun 28. [PMID: 20689733 DOI: 10.1155/2010/309780] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
196 Eckel F, Herrmann K, Schmidt S, Hillerer C, Wieder HA, Krause BJ, Schuster T, Langer R, Wester HJ, Schmid RM. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine. J Nucl Med. 2009;50:1441-1447. [PMID: 19690030 DOI: 10.2967/jnumed.109.065896] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
197 Taddei PJ, Howell RM, Krishnan S, Scarboro SB, Mirkovic D, Newhauser WD. Risk of second malignant neoplasm following proton versus intensity-modulated photon radiotherapies for hepatocellular carcinoma. Phys Med Biol 2010;55:7055-65. [PMID: 21076199 DOI: 10.1088/0031-9155/55/23/S07] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
198 Luo LM, Xia H, Shi R, Zeng J, Liu XR, Wei M. The association between aquaporin-1 expression, microvessel density and the clinicopathological features of hepatocellular carcinoma. Oncol Lett 2017;14:7077-84. [PMID: 29344137 DOI: 10.3892/ol.2017.7106] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
199 Park MJ, Kim SY, Yoon SM, Kim JH, Park SH, Lee SS, Lee Y, Lee MG. Stereotactic body radiotherapy-induced arterial hypervascularity of non-tumorous hepatic parenchyma in patients with hepatocellular carcinoma: potential pitfalls in tumor response evaluation on multiphase computed tomography. PLoS One 2014;9:e90327. [PMID: 24587326 DOI: 10.1371/journal.pone.0090327] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
200 El-shazly SF, Eid MA, El-sourogy HA, Attia GF, Ezzat SA. Evaluation of Serum Dna Integrity as a Screening and Prognostic Tool in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma. Int J Biol Markers 2010;25:79-86. [DOI: 10.1177/172460081002500204] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 8.3] [Reference Citation Analysis]
201 Feun L, Savaraj N. Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin Investig Drugs 2006;15:815-22. [PMID: 16787144 DOI: 10.1517/13543784.15.7.815] [Cited by in Crossref: 78] [Cited by in F6Publishing: 65] [Article Influence: 5.2] [Reference Citation Analysis]
202 Takayama T. Surgical treatment for hepatocellular carcinoma. Jpn J Clin Oncol. 2011;41:447-454. [PMID: 21411469 DOI: 10.1093/jjco/hyr016] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
203 Zhou J, Wan B, Liu XM, Li R, Wang Y, Yu L. MK5 is degraded in response to doxorubicin and negatively regulates doxorubicin-induced apoptosis in hepatocellular carcinoma cells. Biochem Biophys Res Commun 2012;427:581-6. [PMID: 23022185 DOI: 10.1016/j.bbrc.2012.09.101] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
204 Barash H, R Gross E, Edrei Y, Ella E, Israel A, Cohen I, Corchia N, Ben-Moshe T, Pappo O, Pikarsky E, Goldenberg D, Shiloh Y, Galun E, Abramovitch R. Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. Proc Natl Acad Sci U S A 2010;107:2207-12. [PMID: 20133864 DOI: 10.1073/pnas.0908867107] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 7.4] [Reference Citation Analysis]
205 Choi M, Philip PA. Liver-directed therapies for hepatocellular cancer. Community Oncology 2007;4:571-5. [DOI: 10.1016/s1548-5315(11)70037-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
206 Davidson BR, Gurusamy K. Is preoperative histological diagnosis necessary for cholangiocarcinoma? HPB (Oxford) 2008;10:94-7. [PMID: 18773063 DOI: 10.1080/13651820801992633] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
207 Montella M, D'Arena G, Crispo A, Capunzo M, Nocerino F, Grimaldi M, Barbieri A, D'Ursi AM, Tecce MF, Amore A, Galdiero M, Ciliberto G, Giudice A. Role of Sex Hormones in the Development and Progression of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Int J Endocrinol 2015;2015:854530. [PMID: 26491442 DOI: 10.1155/2015/854530] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
208 Stampfl S, Stampfl U, Rehnitz C, Schnabel P, Satzl S, Christoph P, Henn C, Thomas F, Richter GM. Experimental evaluation of early and long-term effects of microparticle embolization in two different mini-pig models. Part II: liver. Cardiovasc Intervent Radiol. 2007;30:462-468. [PMID: 17342551 DOI: 10.1007/s00270-005-0350-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
209 Cho ES, Choi JY. MRI features of hepatocellular carcinoma related to biologic behavior. Korean J Radiol. 2015;16:449-464. [PMID: 25995679 DOI: 10.3348/kjr.2015.16.3.449] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
210 Gao M, Xu H, Zhang C, Liu K, Bao X, Chu Q, He Y, Tian Y. Preparation and characterization of curcumin thermosensitive hydrogels for intratumoral injection treatment. Drug Development and Industrial Pharmacy 2014;40:1557-64. [DOI: 10.3109/03639045.2013.838579] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
211 Iñarrairaegui M, Sangro B. Diagnóstico del hepatocarcinoma de pequeño tamaño. Gastroenterología y Hepatología 2007;30:498-505. [DOI: 10.1157/13110493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
212 Alisi A, Balsano C. Enhancing the Efficacy of Hepatocellular Carcinoma Chemotherapeutics with Natural Anticancer Agents. Nutrition Reviews 2007;65:550-3. [DOI: 10.1111/j.1753-4887.2007.tb00280.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
213 Sugimachi K, Ikeda Y, Tomikawa M, Taketomi A, Tsukamoto S, Kawasaki K, Yamamura S, Korenaga D, Maehara Y, Takenaka K. Appraisal of hepatic resection in the treatment of hepatocellular carcinoma with severe thrombocytopenia. World J Surg. 2008;32:1077-1081. [PMID: 18338210 DOI: 10.1007/s00268-007-9442-3.] [Reference Citation Analysis]
214 Park KW, Park JW, Choi JI, Kim TH, Kim SH, Park HS, Lee WJ, Park SJ, Hong EK, Kim CM. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol 2008;23:467-73. [PMID: 17764529 DOI: 10.1111/j.1440-1746.2007.05112.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 79] [Article Influence: 5.9] [Reference Citation Analysis]
215 Kim JH, Lee SC, Ro J, Kang HS, Kim HS, Yoon S. Jnk signaling pathway-mediated regulation of Stat3 activation is linked to the development of doxorubicin resistance in cancer cell lines. Biochem Pharmacol. 2010;79:373-380. [PMID: 19766599 DOI: 10.1016/j.bcp.2009.09.008] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 4.3] [Reference Citation Analysis]
216 Olsen SK, Brown RS, Siegel AB. Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol. 2010;3:55-66. [PMID: 21180590 DOI: 10.1177/1756283x09346669] [Cited by in Crossref: 49] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
217 Zhang Y, Zhang B, Zhang A, Zhao Y, Zhao J, Liu J, Gao J, Fang D, Rao Z. Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells. Clinics (Sao Paulo) 2012;67:1093-9. [PMID: 23018309 DOI: 10.6061/clinics/2012(09)18] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
218 Yu G, Li H, Yang S, Wen J, Niu J, Zu Y. ssDNA Aptamer Specifically Targets and Selectively Delivers Cytotoxic Drug Doxorubicin to HepG2 Cells. PLoS One 2016;11:e0147674. [PMID: 26808385 DOI: 10.1371/journal.pone.0147674] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
219 Hu G, Li Y, Yang Y, Shi W, Liao A, Yao Y, Zeng B, Yuan J. High expression of Golgi phosphoprotein-3 is associated with poor survival in patients with hepatocellular carcinoma. Tumor Biol 2014;35:8625-32. [DOI: 10.1007/s13277-014-2105-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
220 Changchien CS, Chen CL, Yen YH, Wang JH, Hu TH, Lee CM, Wang CC, Cheng YF, Huang YJ, Lin CY. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. J Gastroenterol. 2008;43:159-170. [PMID: 18306990 DOI: 10.1007/s00535-007-2134-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
221 Ortiz C, Caja L, Sancho P, Bertran E, Fabregat I. Inhibition of the EGF receptor blocks autocrine growth and increases the cytotoxic effects of doxorubicin in rat hepatoma cells. Biochemical Pharmacology 2008;75:1935-45. [DOI: 10.1016/j.bcp.2008.02.015] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
222 Yang TS, Lu SN, Chao Y, Sheen IS, Lin CC, Wang TE, Chen SC, Wang JH, Liao LY, Thomson JA, Wang-Peng J, Chen PJ, Chen LT. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer. 2010;103:954-960. [PMID: 20808309 DOI: 10.1038/sj.bjc.6605856] [Cited by in Crossref: 104] [Cited by in F6Publishing: 95] [Article Influence: 9.5] [Reference Citation Analysis]
223 Dubel GJ, Soares GM. Regional infusion-radioembolization. Surg Oncol Clin N Am 2008;17:957-85, xii. [PMID: 18722928 DOI: 10.1016/j.soc.2008.04.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
224 Nishikawa H, Osaki Y, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Henmi S, Sakamoto A, Ishikawa T, Saito S. Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol. 2012;18:1379-1384. [PMID: 22493552 DOI: 10.3748/wjg.v18.i12.1379] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
225 Yu XX, Ge KL, Liu N, Zhang JY, Xue ML, Ge YL. Selection and Characterization of a Novel DNA Aptamer, Apt-07S Specific to Hepatocellular Carcinoma Cells. Drug Des Devel Ther 2020;14:1535-45. [PMID: 32368012 DOI: 10.2147/DDDT.S244149] [Reference Citation Analysis]
226 Miyahara K, Nouso K, Tomoda T, Kobayashi S, Hagihara H, Kuwaki K, Toshimori J, Onishi H, Ikeda F, Miyake Y. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26:1604-1611. [PMID: 22011296 DOI: 10.1111/j.1440-1746.2011.06887.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
227 Li Y, Ruan DY, Jia CC, Zhao H, Wang GY, Yang Y, Jiang N. Surgical resection versus liver transplantation for hepatocellular carcinoma within the Hangzhou criteria: a preoperative nomogram-guided treatment strategy. Hepatobiliary Pancreat Dis Int 2017;16:480-6. [PMID: 28992879 DOI: 10.1016/S1499-3872(17)60052-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
228 Guo JH, Liu SX, Gao S, Kou FX, Zhang X, Wu D, Li XT, Chen H, Wang XD, Liu P, Zhang PJ, Xu HF, Cao G, Zhu LZ, Yang RJ, Zhu X. Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma. World J Gastroenterol 2020;26:3975-88. [PMID: 32774071 DOI: 10.3748/wjg.v26.i27.3975] [Reference Citation Analysis]
229 Takeshita S, Ichikawa T, Nakao K, Miyaaki H, Shibata H, Matsuzaki T, Muraoka T, Honda T, Otani M, Akiyama M, Miuma S, Ozawa E, Fujimito M, Eguchi K. A snack enriched with oral branched-chain amino acids prevents a fall in albumin in patients with liver cirrhosis undergoing chemoembolization for hepatocellular carcinoma. Nutr Res. 2009;29:89-93. [PMID: 19285598 DOI: 10.1016/j.nutres.2008.12.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
230 Asham EH, Kaseb A, Ghobrial RM. Management of Hepatocellular Carcinoma. Surgical Clinics of North America 2013;93:1423-50. [DOI: 10.1016/j.suc.2013.08.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
231 Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015;9:765-779. [PMID: 25827821 DOI: 10.1586/17474124.2015.1028363] [Cited by in Crossref: 181] [Cited by in F6Publishing: 156] [Article Influence: 30.2] [Reference Citation Analysis]
232 Kim DY, Kim JW, Kuromatsu R, Ahn SH, Torimura T, Sherman M. Controversies in surveillance and early diagnosis of hepatocellular carcinoma. Oncology. 2011;81 Suppl 1:56-60. [PMID: 22212937 DOI: 10.1159/000333261] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
233 Pan Q, Pan K, Weng D, Zhao J, Zhang X, Wang D, Lv L, Jiang S, Zheng H, Xia J. Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma: ANXA3 IN HCC TUMORIGENESIS AND RESISTANCE. Mol Carcinog 2015;54:598-607. [DOI: 10.1002/mc.22126] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
234 Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Müllhaupt B, Clavien PA. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg. 2009;96:975-981. [PMID: 19672926 DOI: 10.1002/bjs.6731] [Cited by in Crossref: 108] [Cited by in F6Publishing: 101] [Article Influence: 9.0] [Reference Citation Analysis]
235 Vogl TJ, Schwarz W, Eichler K, Hochmuth K, Hammerstingl R, Jacob U, Scheller A, Zangos S, Heller M. Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. J Cancer Res Clin Oncol. 2006;132:745-755. [PMID: 16858591 DOI: 10.1007/s00432-006-0138-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
236 Lee NPY, Leung K, Cheung N, Lam BY, Xu MZ, Sham PC, Lau GK, Poon RTP, Fan ST, Luk JM. Comparative proteomic analysis of mouse livers from embryo to adult reveals an association with progression of hepatocellular carcinoma. Proteomics 2008;8:2136-49. [DOI: 10.1002/pmic.200700590] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
237 Park JO, Ryoo BY, Yen CJ, Kudo M, Yang L, Abada PB, Cheng R, Orlando M, Zhu AX, Okusaka T. Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis. Oncotarget. 2016;7:75482-75491. [PMID: 27776351 DOI: 10.18632/oncotarget.12780] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
238 Wilson GK, Brimacombe CL, Rowe IA, Reynolds GM, Fletcher NF, Stamataki Z, Bhogal RH, Simões ML, Ashcroft M, Afford SC, Mitry RR, Dhawan A, Mee CJ, Hübscher SG, Balfe P, McKeating JA. A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migration. J Hepatol 2012;56:803-9. [PMID: 22178269 DOI: 10.1016/j.jhep.2011.11.018] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 5.5] [Reference Citation Analysis]
239 Chen X, Wu W, Ding J. Aberrant TIG1 methylation associated with its decreased expression and clinicopathological significance in hepatocellular carcinoma. Tumor Biol 2014;35:967-71. [DOI: 10.1007/s13277-013-1129-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
240 Bae SH, Kim MS, Jang WI, Kay CS, Kim W, Kim ES, Kim JH, Kim JH, Yang KM, Lee KC. Practical patterns for stereotactic body radiotherapy to hepatocellular carcinoma in Korea: a survey of the Korean Stereotactic Radiosurgery Group. Jpn J Clin Oncol. 2016;46:363-369. [PMID: 26826720 DOI: 10.1093/jjco/hyv209] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
241 Hata M, Tokuuye K, Sugahara S, Fukumitsu N, Hashimoto T, Ohnishi K, Nemoto K, Ohara K, Matsuzaki Y, Akine Y. Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis. Strahlenther Onkol 2006;182:713-20. [PMID: 17149578 DOI: 10.1007/s00066-006-1564-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
242 Zheng YS, Zhang JY, Zhang DH. Fatsioside A‑induced apoptotic death of HepG2 cells requires activation of AMP‑activated protein kinase. Mol Med Rep 2015;12:5679-84. [PMID: 26252753 DOI: 10.3892/mmr.2015.4194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
243 Park SH, Kim JC, Kang MK. Technical advances in external radiotherapy for hepatocellular carcinoma. World J Gastroenterol 2016;22:7311-21. [PMID: 27621577 DOI: 10.3748/wjg.v22.i32.7311] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
244 Korean Society of Abdominal Radiology. Diagnosis of Hepatocellular Carcinoma with Gadoxetic Acid-Enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology. Korean J Radiol 2017;18:427-43. [PMID: 28458595 DOI: 10.3348/kjr.2017.18.3.427] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
245 Martens V, Schlichting S, Besirevic A, Kleemann M. LapAssistent — a laparoscopic liver surgery assistance system. In: Vander Sloten J, Verdonck P, Nyssen M, Haueisen J, editors. 4th European Conference of the International Federation for Medical and Biological Engineering. Berlin: Springer Berlin Heidelberg; 2009. pp. 121-5. [DOI: 10.1007/978-3-540-89208-3_31] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
246 Mas VR, Fisher RA, Archer KJ, Yanek KC, Williams B, Dumur CI, Maluf DG. Genes Associated With Progression and Recurrence of Hepatocellular Carcinoma in Hepatitis C Patients Waiting and Undergoing Liver Transplantation: Preliminary Results. Transplantation 2007;83:973-81. [DOI: 10.1097/01.tp.0000258643.05294.0b] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
247 Amesur NB, Zajko AB, Carr BI. Chemo-embolization for Unresectable Hepatocellular Carcinoma with Different Sizes of Embolization Particles. Dig Dis Sci 2008;53:1400-4. [DOI: 10.1007/s10620-007-9995-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
248 Xu Y, Yi Y, Qiu S, Gao Q, Li Y, Dai C, Cai M, Ju M, Zhou J, Zhang B, Fan J. PEBP1 downregulation is associated to poor prognosis in HCC related to hepatitis B infection. Journal of Hepatology 2010;53:872-9. [DOI: 10.1016/j.jhep.2010.05.019] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 5.7] [Reference Citation Analysis]
249 Kim YJ, Goh PG, Moon HS, Lee ES, Kim SH, Lee BS, Lee HY. Reactivation of tuberculosis in hepatocellular carcinoma treated with transcatheter arterial chemoembolization: A report of 3 cases. World J Radiol 2012;4:236-40. [PMID: 22761986 DOI: 10.4329/wjr.v4.i5.236] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
250 Virmani S, Rhee TK, Ryu RK, Sato KT, Lewandowski RJ, Mulcahy MF, Kulik LM, Szolc-Kowalska B, Woloschak GE, Yang GY, Salem R, Larson AC, Omary RA. Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. J Vasc Interv Radiol 2008;19:1483-9. [PMID: 18922400 DOI: 10.1016/j.jvir.2008.06.017] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 5.0] [Reference Citation Analysis]
251 Delis SG, Dervenis C. Selection criteria for liver resection in patients with hepatocellular carcinoma and chronic liver disease. World J Gastroenterol. 2008;14:3452-3460. [PMID: 18567070 DOI: 10.3748/wjg.14.3452] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
252 Dobbins C, Wemyss-Holden SA, Cockburn J, Maddern GJ. Bimodal electric tissue ablation-modified radiofrequency ablation with a le veen electrode in a pig model. J Surg Res 2008;144:111-6. [PMID: 17640668 DOI: 10.1016/j.jss.2007.03.066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
253 Ye SL, Takayama T, Geschwind J, Marrero JA, Bronowicki JP. Current approaches to the treatment of early hepatocellular carcinoma. Oncologist. 2010;15 Suppl 4:34-41. [PMID: 21115579 DOI: 10.1634/theoncologist.2010-s4-34] [Cited by in Crossref: 36] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
254 Sonnenday CJ, Dimick JB, Schulick RD, Choti MA. Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma. J Gastrointest Surg 2007;11:1636-46; discussion 1646. [PMID: 17912593 DOI: 10.1007/s11605-007-0315-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
255 Bae SH, Kim MS, Cho CK, Kim KB, Lee DH, Han CJ, Park SC, Kim YH. Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona Clinic Liver Cancer-C stage hepatocellular carcinoma. J Korean Med Sci. 2013;28:213-219. [PMID: 23400333 DOI: 10.3346/jkms.2013.28.2.213] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
256 Lee NP, Cheung ST, Poon RT, Fan ST, Luk JM. Genomic and proteomic biomarkers for diagnosis and prognosis of hepatocellular carcinoma. Biomark Med 2007;1:273-84. [PMID: 20477402 DOI: 10.2217/17520363.1.2.273] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
257 Guglielmi A, Ruzzenente A, Pachera S, Valdegamberi A, Sandri M, D’Onofrio M, Iacono C. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol. 2008;103:597-604. [PMID: 17970836 DOI: 10.1111/j.1572-0241.2007.01604.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 5.0] [Reference Citation Analysis]
258 Lewis AL, Gonzalez MV, Leppard SW, Brown JE, Stratford PW, Phillips GJ, Lloyd AW. Doxorubicin eluting beads - 1: effects of drug loading on bead characteristics and drug distribution. J Mater Sci Mater Med. 2007;18:1691-1699. [PMID: 17483878 DOI: 10.1007/s10856-007-3068-8] [Cited by in Crossref: 121] [Cited by in F6Publishing: 103] [Article Influence: 8.6] [Reference Citation Analysis]
259 Choi D, Lim HK, Joh JW, Kim SJ, Kim MJ, Rhim H, Kim YS, Yoo BC, Paik SW, Park CK. Combined hepatectomy and radiofrequency ablation for multifocal hepatocellular carcinomas: long-term follow-up results and prognostic factors. Ann Surg Oncol. 2007;14:3510-3518. [PMID: 17653800 DOI: 10.1245/s10434-007-9492-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
260 Albiin N. MRI of Focal Liver Lesions. Curr Med Imaging Rev. 2012;8:107-116. [PMID: 23049491 DOI: 10.2174/157340512800672216] [Cited by in Crossref: 45] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
261 Kim JH, Kim TH, Kang HS, Ro J, Kim HS, Yoon S. SP600125, an inhibitor of Jnk pathway, reduces viability of relatively resistant cancer cells to doxorubicin. Biochem Biophys Res Commun. 2009;387:450-455. [PMID: 19607816 DOI: 10.1016/j.bbrc.2009.07.036] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
262 Wong J, Lee KF, Yu SC, Lee PS, Cheung YS, Chong CN, Ip PC, Lai PB. Percutaneous radiofrequency ablation versus surgical radiofrequency ablation for malignant liver tumours: the long-term results. HPB (Oxford) 2013;15:595-601. [PMID: 23458320 DOI: 10.1111/hpb.12014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
263 Baldassarre F, Vergaro V, Scarlino F, De Santis F, Lucarelli G, Torre AD, Ciccarella G, Rinaldi R, Giannelli G, Leporatti S. Polyelectrolyte Capsules as Carriers for Growth Factor Inhibitor Delivery to Hepatocellular Carcinoma: Polyelectrolyte Capsules as Carriers for Growth Factor Inhibitor Delivery …. Macromol Biosci 2012;12:656-65. [DOI: 10.1002/mabi.201100457] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
264 Sugimachi K, Matsumura T, Hirata H, Uchi R, Ueda M, Ueo H, Shinden Y, Iguchi T, Eguchi H, Shirabe K, Ochiya T, Maehara Y, Mimori K. Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br J Cancer. 2015;112:532-538. [PMID: 25584485 DOI: 10.1038/bjc.2014.621] [Cited by in Crossref: 171] [Cited by in F6Publishing: 150] [Article Influence: 28.5] [Reference Citation Analysis]
265 Li JH, Yao RR, Shen HJ, Zhang L, Xie XY, Chen RX, Wang YH, Ren ZG. Clostridium perfringens infection after transarterial chemoembolization for large hepatocellular carcinoma. World J Gastroenterol. 2015;21:4397-4401. [PMID: 25892893 DOI: 10.3748/wjg.v21.i14.4397] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
266 Choi D, Lim HK, Rhim H. Concurrent and subsequent radiofrequency ablation combined with hepatectomy for hepatocellular carcinomas. World J Gastrointest Surg. 2010;2:137-142. [PMID: 21160862 DOI: 10.4240/wjgs.v2.i4.137] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
267 Chen H, Sun LY, Zheng HQ, Zhang QF, Jin XM. Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma. Pathology 2012;44:318-24. [PMID: 22531347 DOI: 10.1097/PAT.0b013e328353a24c] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
268 Chen MC, Chen CH, Chuang HC, Kulp SK, Teng CM, Chen CS. Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIα degradation in hepatocellular carcinoma cells. Hepatology. 2011;53:148-159. [PMID: 21254166 DOI: 10.1002/hep.23964] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
269 Yang XX, Sun JZ, Li FX, Wu YS, Du HY, Zhu W, Li XH, Li M. Aberrant methylation and downregulation of sall3 in human hepatocellular carcinoma. World J Gastroenterol. 2012;18:2719-2726. [PMID: 22690083 DOI: 10.3748/wjg.v18.i21.2719] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
270 Franssen B, Alshebeeb K, Tabrizian P, Marti J, Pierobon ES, Lubezky N, Roayaie S, Florman S, Schwartz ME. Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center. Ann Surg. 2014;260:650-656; discussion 656-658. [PMID: 25203882 DOI: 10.1097/sla.0000000000000917] [Cited by in Crossref: 58] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
271 Norén A, Urdzik J, Duraj F, Barbier CE, Karlson BM, Haglund U. Longterm follow-up after transarterial chemotherapy for hepatocellular carcinoma in a Scandinavian centre. HPB (Oxford) 2010;12:637-43. [PMID: 20961372 DOI: 10.1111/j.1477-2574.2010.00210.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
272 Santi V, Buccione D, Di Micoli A, Fatti G, Frigerio M, Farinati F, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Bernardi M, Trevisani F. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. Journal of Hepatology 2012;56:397-405. [DOI: 10.1016/j.jhep.2011.05.026] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 8.0] [Reference Citation Analysis]
273 Zhu Z, Wang X, Yuan K, Huang J, Zeng Y. Transarterial chemoembolization plus iodine-125 implantation for hepatocellular carcinoma: a systematic review and meta-analysis. HPB 2018;20:795-802. [DOI: 10.1016/j.hpb.2018.03.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
274 Li Y, Martin RC 2nd. Herbal medicine and hepatocellular carcinoma: applications and challenges. Evid Based Complement Alternat Med 2011;2011:541209. [PMID: 21799681 DOI: 10.1093/ecam/neq044] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
275 Yoon S, Kim JH, Lee YJ, Ahn MY, Choi G, Kim WK, Yang Z, Lee HJ, Moon HR, Kim HS. A novel carbazole derivative, MHY407, sensitizes cancer cells to doxorubicin-, etoposide-, and radiation treatment via DNA damage. Eur J Pharmacol 2012;697:24-31. [PMID: 23085270 DOI: 10.1016/j.ejphar.2012.10.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
276 Cheung TT, Ng KK, Chok KS, Chan SC, Poon RT, Lo CM, Fan ST. Combined resection and radiofrequency ablation for multifocal hepatocellular carcinoma: prognosis and outcomes. World J Gastroenterol. 2010;16:3056-3062. [PMID: 20572310 DOI: 10.3748/wjg.v16.i24.3056] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
277 Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. ISRN Hepatol. 2014;25:154-159. [PMID: 27335840 DOI: 10.1155/2014/706945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
278 Xue T, Feng W, Yu H, Zhu M, Fei M, Bao Y, Wang X, Ma W, Lv G, Guan J, Chen S. Metastasis-Associated Protein 1 Is Involved in Angiogenesis after Transarterial Chemoembolization Treatment. Biomed Res Int 2017;2017:6757898. [PMID: 28589145 DOI: 10.1155/2017/6757898] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
279 Lu Y, Yue X, Cui Y, Zhang J, Wang K. MicroRNA-124 suppresses growth of human hepatocellular carcinoma by targeting STAT3. Biochem Biophys Res Commun. 2013;441:873-879. [PMID: 24211205 DOI: 10.1016/j.bbrc.2013.10.157] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
280 Wu L, Li L, Meng S, Qi R, Mao Z, Lin M. Expression of argininosuccinate synthetase in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28:365-368. [PMID: 23339388 DOI: 10.1111/jgh.12043] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
281 Li H, Rong Z, Wang H, Zhang N, Pu C, Zhao Y, Zheng X, Lei C, Liu Y, Luo X, Chen J, Wang F, Wang A, Wang J. Proteomic analysis revealed common, unique and systemic signatures in gender-dependent hepatocarcinogenesis. Biol Sex Differ 2020;11:46. [PMID: 32792008 DOI: 10.1186/s13293-020-00316-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
282 Mazzocca A, Fransvea E, Dituri F, Lupo L, Antonaci S, Giannelli G. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology. 2010;51:523-534. [PMID: 19821534 DOI: 10.1002/hep.23285] [Cited by in Crossref: 113] [Cited by in F6Publishing: 112] [Article Influence: 10.3] [Reference Citation Analysis]
283 Mao Y, Du S, Ba J, Li F, Yang H, Lu X, Sang X, Li S, Che L, Tong J. Using Dynamic 99mT c-GSA SPECT/CT fusion images for hepatectomy planning and postoperative liver failure prediction. Ann Surg Oncol. 2015;22:1301-1307. [PMID: 25294018 DOI: 10.1245/s10434-014-4117-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
284 Adachi T, Nouso K, Miyahara K, Oyama A, Wada N, Dohi C, Takeuchi Y, Yasunaka T, Onishi H, Ikeda F, Nakamura S, Shiraha H, Takaki A, Takabatake H, Fujioka SI, Kobashi H, Takuma Y, Iwadou S, Uematsu S, Takaguchi K, Hagihara H, Okada H; Okayama Liver Cancer Group. Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib. J Gastroenterol Hepatol. 2019;34:1081-1087. [PMID: 30402928 DOI: 10.1111/jgh.14535] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
285 Stiuso P, Potenza N, Lombardi A, Ferrandino I, Monaco A, Zappavigna S, Vanacore D, Mosca N, Castiello F, Porto S, Addeo R, Prete SD, De Vita F, Russo A, Caraglia M. MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib. Molecular Therapy - Nucleic Acids 2015;4:e233. [DOI: 10.1038/mtna.2015.8] [Cited by in Crossref: 91] [Cited by in F6Publishing: 82] [Article Influence: 15.2] [Reference Citation Analysis]
286 Colombino M, Sperlongano P, Izzo F, Tatangelo F, Botti G, Lombardi A, Accardo M, Tarantino L, Sordelli I, Agresti M, Abbruzzese A, Caraglia M, Palmieri G. BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death Dis 2012;3:e259. [PMID: 22258409 DOI: 10.1038/cddis.2011.136] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 5.8] [Reference Citation Analysis]
287 Shen JY, Li C, Wen TF, Yan LN, Li B, Wang WT, Yang JY, Xu MQ. Alpha fetoprotein changes predict hepatocellular carcinoma survival beyond the Milan criteria after hepatectomy. J Surg Res. 2017;209:102-111. [PMID: 28032546 DOI: 10.1016/j.jss.2016.10.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
288 Teixeira R, Marcos LA, Friedman SL. Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C. Hepatology Research 2007;37:579-95. [DOI: 10.1111/j.1872-034x.2007.00085.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
289 Moser C, Lang SA, Mori A, Hellerbrand C, Schlitt HJ, Geissler EK, Fogler WE, Stoeltzing O. ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo. BMC Cancer 2008;8:206. [PMID: 18651980 DOI: 10.1186/1471-2407-8-206] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
290 Kong L, Li M, Li L, Jiang L, Yang J, Yan L. Splenectomy before adult liver transplantation: a retrospective study. BMC Surg 2017;17:44. [PMID: 28427382 DOI: 10.1186/s12893-017-0243-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
291 Guo Y, Zhang Y, Li J, Zhang Y, Lu Y, Jiang X, He X, Ma H, An S, Jiang C. Cell microenvironment-controlled antitumor drug releasing-nanomicelles for GLUT1-targeting hepatocellular carcinoma therapy. ACS Appl Mater Interfaces 2015;7:5444-53. [PMID: 25686400 DOI: 10.1021/am5091462] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
292 Kalva SP, Pectasides M, Liu R, Rachamreddy N, Surakanti S, Yeddula K, Ganguli S, Wicky S, Blaszkowsky LS, Zhu AX. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2014;37:381-387. [PMID: 23754191 DOI: 10.1007/s00270-013-0654-7] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
293 Kim JH, Chae M, Kim WK, Kim YJ, Kang HS, Kim HS, Yoon S. Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein. Br J Pharmacol. 2011;162:773-784. [PMID: 20973777 DOI: 10.1111/j.1476-5381.2010.01089.x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 9.9] [Reference Citation Analysis]
294 Kang J, Nie Q, DU R, Zhang L, Zhang J, Li Q, Li J, Qi W. Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Mol Clin Oncol. 2014;2:43-50. [PMID: 24649306 DOI: 10.3892/mco.2013.196] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
295 Malek NP, Greten T, Kubicka S. Systemische Therapie von Leber- und Gallenwegstumoren. Internist 2007;48:46-50. [DOI: 10.1007/s00108-006-1774-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
296 Sapisochin G, de Sevilla EF, Echeverri J, Charco R. Management of “very early” hepatocellular carcinoma on cirrhotic patients. World J Hepatol. 2014;6:766-775. [PMID: 25429314 DOI: 10.4254/wjh.v6.i11.766] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
297 Lee SS, Shin HS, Kim HJ, Lee SJ, Lee HS, Hyun KH, Kim YH, Kwon BW, Han JH, Choi H, Kim BH, Lee JH, Kang HY, Shin HD, Song IH. Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience. Korean J Hepatol 2012;18:48-55. [PMID: 22511903 DOI: 10.3350/kjhep.2012.18.1.48] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
298 Matsubara M, Shiraha H, Kataoka J, Iwamuro M, Horiguchi S, Nishina S, Takaoka N, Uemura M, Takaki A, Nakamura S. Des-γ-carboxyl prothrombin is associated with tumor angiogenesis in hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27:1602-1608. [PMID: 22554292 DOI: 10.1111/j.1440-1746.2012.07173.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
299 Mohkam K, Golse N, Bonal M, Ledochowski S, Rode A, Selmaji IE, Merle P, Ducerf C, Mornex F, Mabrut J. Conformal radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma: is it safe? Future Oncology 2016;12:1577-86. [DOI: 10.2217/fon-2016-0083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
300 Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, Loo HL, Aung MO, Lim SG, Ullrich A. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. Journal of Hepatology 2009;50:118-27. [DOI: 10.1016/j.jhep.2008.08.015] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 8.8] [Reference Citation Analysis]
301 Chang C, Lee SO, Yeh S, Chang TM. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene. 2014;33:3225-3234. [PMID: 23873027 DOI: 10.1038/onc.2013.274] [Cited by in Crossref: 118] [Cited by in F6Publishing: 103] [Article Influence: 14.8] [Reference Citation Analysis]
302 Barazani Y, Hiatt JR, Tong MJ, Busuttil RW. Chronic viral hepatitis and hepatocellular carcinoma. World J Surg 2007;31:1243-8. [PMID: 17440771 DOI: 10.1007/s00268-007-9041-3] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 4.9] [Reference Citation Analysis]
303 Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. Hepatol Res 2015;45:59-74. [PMID: 24965914 DOI: 10.1111/hepr.12378] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 7.4] [Reference Citation Analysis]
304 Wang H, Jiang S, Zhang Y, Pan K, Xia J, Chen M. High expression of thymosin beta 10 predicts poor prognosis for hepatocellular carcinoma after hepatectomy. World J Surg Oncol 2014;12:226. [PMID: 25037578 DOI: 10.1186/1477-7819-12-226] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
305 Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Lee RC, Chiou YY, Huo TI. Hepatocellular carcinoma in uremic patients: is there evidence for an increased risk of mortality? J Gastroenterol Hepatol. 2013;28:348-356. [PMID: 23190248 DOI: 10.1111/jgh.12062] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
306 Nouso K, Kobayashi Y, Nakamura S, Kobayashi S, Toshimori J, Kuwaki K, Hagihara H, Onishi H, Miyake Y, Ikeda F, Shiraha H, Takaki A, Iwasaki Y, Kobashi H, Yamamoto K. Evolution of prognostic factors in hepatocellular carcinoma in Japan. Alimentary Pharmacology & Therapeutics 2010;31:407-14. [DOI: 10.1111/j.1365-2036.2009.04179.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
307 Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 2014;273:30-50. [PMID: 25247563 DOI: 10.1148/radiol.14132362] [Cited by in Crossref: 256] [Cited by in F6Publishing: 166] [Article Influence: 42.7] [Reference Citation Analysis]
308 Menon KV, Hakeem AR, Heaton ND. Review article: liver transplantation for hepatocellular carcinoma - a critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther 2014;40:893-902. [DOI: 10.1111/apt.12922] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
309 Yang H, Xu M, Chi X, Yan Q, Wang Y, Xu W, Zhuang K, Li A, Liu S. Higher PKD3 expression in hepatocellular carcinoma (HCC) tissues predicts poorer prognosis for HCC patients. Clin Res Hepatol Gastroenterol 2017;41:554-63. [PMID: 28363424 DOI: 10.1016/j.clinre.2017.02.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
310 Lu S, Wu J, Gao Y, Han G, Ding W, Huang X. MicroRNA-4262 activates the NF-κB and enhances the proliferation of hepatocellular carcinoma cells. International Journal of Biological Macromolecules 2016;86:43-9. [DOI: 10.1016/j.ijbiomac.2016.01.019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
311 Hsu Y, Fu H, Jeng Y, Lee P, Yang S. Proline-Directed Protein Kinase F A Is a Powerful and Independent Prognostic Predictor for Progression and Patient Survival of Hepatocellular Carcinoma. JCO 2006;24:3780-8. [DOI: 10.1200/jco.2005.03.7499] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
312 Sun P, Yang X, He RQ, Hu QG, Song ZF, Xiong J, Zheng QC. Antiviral therapy after curative treatment of hepatitis B/C virus-related hepatocellular carcinoma: A systematic review of randomized trials. Hepatol Res. 2014;44:259-269. [PMID: 23607290 DOI: 10.1111/hepr.12115] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
313 Rempp H, Waibel L, Hoffmann R, Claussen CD, Pereira PL, Clasen S. MR-guided radiofrequency ablation using a wide-bore 1.5-T MR system: clinical results of 213 treated liver lesions. Eur Radiol 2012;22:1972-82. [DOI: 10.1007/s00330-012-2438-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
314 Datta S, Ghosh A, Dasgupta D, Ghosh A, Roychoudhury S, Roy G, Das S, Das K, Gupta S, Basu K, Basu A, Datta S, Chowdhury A, Banerjee S. Novel point and combo-mutations in the genome of hepatitis B virus-genotype D: characterization and impact on liver disease progression to hepatocellular carcinoma. PLoS One 2014;9:e110012. [PMID: 25333524 DOI: 10.1371/journal.pone.0110012] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
315 Somma F, D'Angelo R, Serra N, Gatta G, Grassi R, Fiore F. Use of Ethanol in the Trans-Arterial Lipiodol Embolization (TAELE) of Intermediated-Stage HCC: Is This Safer than Conventional Trans-Arterial Chemo-Embolization (c-TACE)? PLoS One 2015;10:e0129573. [PMID: 26110810 DOI: 10.1371/journal.pone.0129573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
316 Yang B, Zan RY, Wang SY, Li XL, Wei ML, Guo WH, You X, Li J, Liao ZY. Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials. World J Surg Oncol. 2015;13:96. [PMID: 25889181 DOI: 10.1186/s12957-015-0516-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
317 Xiu M, Liu YH, Brigstock DR, He FH, Zhang RJ, Gao RP. Connective tissue growth factor is overexpressed in human hepatocellular carcinoma and promotes cell invasion and growth. World J Gastroenterol 2012;18:7070-8. [PMID: 23323010 DOI: 10.3748/wjg.v18.i47.7070] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
318 Park KW, Park JW, Kim TH, Choi JI, Kim SH, Park HS, Park SJ, Lee WJ, Shin HL, Kim CM. [Five-year survival analysis of a cohort of hepatocellular carcinoma patients who treated at the National Cancer Center, Korea]. Korean J Hepatol 2007;13:530-42. [PMID: 18159151 DOI: 10.3350/kjhep.2007.13.4.530] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
319 Zhu S, Tan W, Li W, Zhou R, Wu X, Chen X, Li W, Shang C, Chen Y. Low expression of VSIG4 is associated with poor prognosis in hepatocellular carcinoma patients with hepatitis B infection. Cancer Manag Res. 2018;10:3697-3705. [PMID: 30288101 DOI: 10.2147/cmar.s165822] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
320 Andrew Schumacher P, Powell JJ, Macneill AJ, Buczkowski AK, Erb SR, Ho SG, Scudamore CH, Stembrecher UP, Weiss A, Yoshida E, Chung SW. Multimodal therapy for hepatocellular carcinoma: A complementary approach to liver transplantation. Annals of Hepatology 2010;9:23-32. [DOI: 10.1016/s1665-2681(19)31675-8] [Cited by in Crossref: 8] [Article Influence: 0.7] [Reference Citation Analysis]